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1.   Targeting chemoresistance induced by MYCN and ALK in neuroblastoma
Louis Chesler
Institute of Cancer Research, London, UK
Neuroblastoma, a tumour of peripheral nerve, is the most common solid tumour of young children and 
in high-risk diseases, which comprises approximately half of patients, and the death from chemoresistant, 
metastatic relapse is very frequent. Children who relapse exhibit clonal enrichment of two genomic altera-
tions: high-level amplification of the MYCN oncogene, and kinase domain mutations of the anaplastic 
lymphoma kinase (ALK) gene. Overall survival in this patient cohort is < 15% at 3 years, and there are few 
options for rationally targeted therapy. Neuroblastoma patients exhibit de novo resistance to existing ALK 
inhibitors, and no clinical therapeutics to target MYCN has yet been developed. This talk will outline our 
efforts to model aberrant expression of MYCN and ALK in neuroblastoma, and to uncover mechanisms of 
oncogenic action that are therapeutically targetable using small-molecule inhibitors. We describe a mecha-
nistic interaction in which ALK upregulates MYCN transcription, and discuss clinical trials emerging from 
our work to develop transcriptional inhibitors of MYCN, and to identify effective inhibitors of ALK in neu-
roblastoma patients. 
2.   Clinical application of single cell analysis
Bernhard Polzer
Fraunhofer Item, Regensburg, Germany
Currently, one in four deaths is caused by cancer, mainly as a result of systemic spread and metastatic dis-
ease. Despite new drugs, the currently available therapies are effective only in one in four cancer patients. 
An initially successful therapy is often followed by a relapse of the disease after a few months only, which 
can be explained by the following two underlying mechanisms: on the one hand, due to the genetic hetero-
geneity found in many types of cancer, it is assumed that resistant tumor cells are already present in many 
patients at the time of therapeutic intervention; on the other hand, the administered drugs result in a selec-
tion of tumor cell clones that have developed de novo mutations favorable for tumor cell survival. Moni-
toring of genetic alterations in the course of systemic cancer disease at close intervals could thus help in 
recognizing the development of resistance at an early stage and in selecting the most appropriate therapy 
for each patient. For this, we established a liquid biopsy platform and single cell technologies to follow the 
genetic evolution of systemic cancer.
3.   The resistant cancer cell line collection: drug-adapted cancer cell lines as preclinical 
      models of acquired drug resistance
Martin Michaelis1, Mark N. Wass1, Cinatl J. Jr2
1Industrial Biotechnology Centre and School of Biosciences, University of Kent, Canterbury, UK
2Institut für Medizinische Virologie, Klinikum der Goethe-Universität, Frankfurt am Main, Germany
Acquired resistance formation is a major reason for the failure of anti-cancer therapies. Pre-clinical model 
systems are needed to complement data derived from clinical specimens such as liquid biopsies to establish 
the understanding of the resistance formation process required to improve therapies. Cancer cell lines en-
able the generation of the large number of model systems needed to cover the complexity of the resistance 
mechanisms. Major resistance mechanisms have been discovered in drug-adapted cell lines, e.g., high 
levels of the ATP-binding cassette (ABC) transporters ABCB1 (also P-glycoprotein, MDR1) and ABCC1 
(also MRP1). Moreover, various groups have used drug-adapted cancer cell lines to identify and elucidate 
clinically relevant acquired resistance mechanisms to targeted and cytotoxic anti-cancer drugs. We have 
established the resistant cancer cell line (RCCL) collection by adapting initially chemosensitive cancer cell 
lines to clinical concentrations of targeted and cytotoxic anti-cancer drugs. It currently contains 1,300 
cancer cell lines based on 125 parental cell lines from 15 cancer entities and reflects acquired resistance to 
67 drugs (https://research.kent.ac.uk/ibc/the-resistant-cancer-cell-line-rccl-collection). Using RCCL collec-
tion cell lines, we and others identified (clinically relevant) drug resistance mechanisms and have gained 
insights into the action of anti-cancer drugs. For example, we have shown that acquisition of resistance to 
MDM2 inhibitors is associated with TP53 mutations, which has been clinically confirmed. Furthermore, 
we have identified high SAMHD1 expression as a resistance mechanism in cytarabine-adapted acute my-
eloid leukaemia cell lines and, in turn, shown that SAMHD1 is a biomarker for cytarabine response in 
the clinic and a novel therapeutic target in acute myeloid leukaemia. In conclusion, drug-adapted cancer 
cell lines reflect clinically relevant acquired drug resistance mechanisms. The RCCL collection is a readily 
available tool containing a substantial number of preclinical models of acquired drug resistance in cancer. 
4.   Prospects and limitations of patient-derived xenografts in translational cancer research
Iduna Fichtner1,2 
1Max Delbrück Center, Berlin, Germany
2Experimental Pharmacology and Oncology GmbH, Berlin, Germany
The molecular analysis of tumours by highly sophisticated gene expression and sequencing methods allows 
the comprehensive identification of drugable targets and the increasing chance for personalized treatments. 
Clinically established examples are the use of Imatinib for BCR-ABL positive leukemias and Vemurafenib 
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for BRAF mutated melanomas. But, in general tumours are characterized by the presence of numerous 
oncogenes, genetic aberrations and a dynamic growth control. That complex and individual pattern even 
nowadays cannot fully be understood and mirrored by medical systems biology. Another attractive option 
to maintain the typical features of a patient tumour is by growing it in a foreign host how it is practised 
since the invention of the patient-derived xenografts (PDX). This method has been used for more than 30 
years but got recently increasing attractivity for the identification of novel biomarkers and as so-called ava-
tars for a patient-related optimization of therapy. Meanwhile, worldwide several thousands of PDX models 
covering the broad variety of tumour types exist and are used both for fundamental research and for com-
mercial offer. It has been proved in several investigations that the PDX highly resemble the original tumour 
specimen concerning histology, molecular marker and response to therapy. Within the talk our own long-
standing experiences concerning the establishment and characterization of PDX will be reflected. Addi-
tional efforts have been made to further “humanize” the mice. For that purpose, in general two procedures 
exist. A transient humanization can be reached by co-transplanting human mononuclear cells or subtypes 
of leukocytes like NK cells. A lifelong humanization of the mouse immune system can be reached by 
transplanting human stem cells. In these humanized mice immunopharmacological drugs like checkpoint 
inhibitors can be functionally tested. Methods and experiences with this sophisticated preclinical model 
system will be presented.
5.     Drug resistance to synthetic lethal treatments for cancer
Chris Lord
The Institute of Cancer Research, London, UK
The first synthetic lethal treatments for cancer, poly (ADP-ribose) polymerase (PARP) inhibitors, are now 
approved for use. Despite PARP inhibitors delivering some sustained and profound clinical responses, drug 
resistance is a growing problem. I will discuss how genetic perturbation screens can identify mechanisms 
of PARP inhibitor resistance and how genetic reversions in BRCA genes, mutations in PARP1 and loss of 
the newly identified Shieldin protein complex can result in PARP inhibitor resistance. I will also discuss 
how the mechanism of PARP inhibitor resistance that emerges defines the sensitivity to other therapeutics.
6.   Assessment of homologous recombination DNA repair function in human tumours and 
       potential for selection of patients for platinum or PARP inhibitor therapy
Nicola Curtin
Newcastle University, UK
All cells experience a high level of base lesions and DNA single strand breaks (SSBs) caused by endog-
enously generated reactive oxygen species. Poly (ADP-ribose) polymerase (PARP) is crucial for the repair 
of SSBs and any left unrepaired will collapse replication forks, which can only be resolved by HRR. We first 
described the selective killing of cells defective in homologous recombination DNA repair (HRR) by PARP 
is in 2005, which has led to an explosion in PARP inhibitor (PARPi) research. BRCA1 and BRCA2, the 
breast and ovarian cancer genes are key components of HRR and 3 PARPi are approved for use in ovarian 
cancer. Since (1) < 20% of ovarian cancers are associated with BRCA mutations; (2) HRR is a multi-compo-
nent pathway such that defects in any one of them may compromise HRR function; and (3) HRR dysfunc-
tion confers sensitivity to platinum agents and 60% of ovarian cancers respond to platinum therapy, we 
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investigated HRR function in primary cultures of cells from ascites taken from patients with ovarian can-
cer. We measured HRR function by the ability to form RAD51 foci following 24 h exposure to rucaparib 
(a PARPi). We found that 55% of our samples were HRR dysfunctional (HRD), this was later reinforced by 
the estimate of 51% HRD by the TCGA, following an extensive genomic analysis. Subsequent work showed 
that those patients identified as HRR defective had better PFS and OS, indicating a better response to Stan-
dard of Care: carboplatin-paclitaxel therapy. We have applied this test to pleural effusions and found HRR 
defects were relatively common, including 3 out of 4 non-small-cell lung cancer samples. More recently 
we have investigated the HRR status of primary cultures of ascites cells taken from patients with a variety 
of different tumour types and found that 8/24 were HRD. Survival of patients treated with platinum was 
greater in the HRD group (n = 3) but this was not significant due to the small number of patients (10 in to-
tal). Our data indicate that HRD is relatively common in a variety of tumour types and the limited data on 
their response to platinum therapy suggest that adoption of either platinum or PARPi therapy in patients 
with any HRD tumour is worthy of investigation.
7.   Pharmaco Epigenetics in human cancer
Manel Esteller
IDBELL, Barcelona, Spain
For the last twenty-five years an increasing amount of evidence has shown the relevance of epigenetics 
in cell biology and tissue physiology, being DNA methylation aberrations in cancer the flag-ship for the 
recognition of its disturbance in human diseases. From the candidate gene approaches, new powerful 
technologies such as comprehensive DNA methylation microarrays and whole genome bisulfite sequencing 
have recently emerged that reinforce the notion of epigenetic disruption in the crossroad of many sickness. 
From the poster-boy cases of MGMT and GSTP1 hypermethylation in the prediction of alkylating drug 
response and prostate cancer detection, respectively, to the personalized treatment of leukemia with small 
molecules targeted to fusion proteins involving histone modifiers such as DOT1L and MLL, the field has 
walked a long path. The current talk will focus on the epigenetic profiling, basically at the level of DNA 
methylation and histone modifications, that is starting to provide clinical value in the diagnosis, prognosis 
and prediction of response to drug therapies, with an emphasis in neoplasia, but without forgetting the 
novel advances in other human disorders. For cancer, we have already a wide view of the undergoing DNA 
methylation events that expand beyond classical promoter CpG islands of tumor suppressor genes and we 
have a growing list of mutated chromatin remodeler genes that contributes to the tumorigenesis process. 
It is time to apply this knowledge in practical clinical situations like the diagnosis of cancers of unknown 
primary, the screening of malignancies in high-risk populations or a biomarker selection of the patients 
that should receive treatment with epigenetic drugs.
8.   A CRISPR-based mutagenesis method for determinants of drug resistance
Daniel J. O’Neill1, Claudia Stellato1, Alexis Guernet1, Mike Firth1, Maryam Clausen2, 
Maria Emanuela Cuomo1
1Discovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, UK
2Discovery Sciences, IMED Biotech Unit, AstraZeneca, Mölndal, Sweden
Acquired drug resistance represents a major challenge in the development of therapeutic agents that show 
long term effectiveness for the treatment of cancer. The problem is exemplified by non-small cell lung 
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cancer (NSCLC) containing activating EGFR mutations. NSCLC tumours driven by EGFR variants are 
initially sensitive to tyrosine kinase inhibitors (TKIs), but some patients show renewed disease progression 
through expansion of tumour cell clones harbouring additional EGFR mutations. Models of drug resis-
tance are therefore necessary to increase our understanding of resistance mechanisms, to predict variants 
that will arise in patients and to improve drug development strategies. CRISPR/Cas9 allows endogenous 
modification of genes and facilitates introduction of all possible mutations at a specific locus, whilst main-
taining endogenous gene architecture, chromosomal context and epigenetic landscape. Here we describe a 
CRISPR-based methodology developed to identify “on target” mutations in key oncogenes that drive phar-
macological resistance. Using EGFR as a target, we show how directed evolution of some residues in the 
EGFR kinase domain can be predictive of the resistance observed in the clinic in response to known TKIs, 
such as gefitinib and osimertinib. In fact, in the region analysed, we can recapitulate the variants observed 
clinically. We also identify amino acids chemically and structurally able to confer resistance to a TKI in 
structurally conserved tyrosine kinases such as BCR-Abl and Kit. The strategy also allows direct genera-
tion of disease relevant cellular models that recapitulate clinical drug resistance.
9.   Molecular data integration for response prediction
Lodewyk Wessels
Netherlands Cancer Institute, Amsterdam, Netherlands
The exact mechanisms involved in tumor development and therapy response are still largely unclear. Here 
we report on two computational approaches to systematically unravel these mechanisms and show how 
these can be employed to predict response to anti-cancer agents. Clinical response to anti-cancer drugs 
varies between patients and is modulated by molecular features. Classic approaches to integrate these 
data for therapy response prediction almost exclusively employ gene expression data. Such predictors are 
difficult to interpret. We developed TANDEM, a two-stage approach in which the first stage explains re-
sponse using upstream features (mutation, copy number and methylation) and the second stage explains 
the remainder using downstream features (gene expression). Applying TANDEM to 934 cell lines profiled 
across 265 drugs we show that the resulting models are more interpretable and equally predictive as classic 
approches. Second, following a more mechanistic integration approach, we constructed Bayesian models 
encompassing several of the important driver pathways and resistance mechanisms, and tested how well 
these models describe drug response data derived from a panel of breast cancer cell lines. The models 
provide estimates of the relative contribution of each of the drivers and resistance mechanisms and allow 
estimation of latent variables such as “pathway activation”. We identify 4EBP1 protein expression as an im-
portant modulator of mTOR inhibitor response.
10.   Mechanisms of therapy resistance in prostate cancer
Charlotte Bevan
Imperial College London, UK
Prostate tumours grow in response to androgens, which act via the androgen receptor (AR). Therapies 
for inoperable, disseminated disease, therefore, are largely designed to inhibit androgen signalling - via 
chemical castration (gonadal downregulation), inhibition of steroidogenesis and/or antiandrogens, which 
directly bind to and inhibit the action of the AR. These are initially successful in the vast majority of pa-
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tients, but almost inevitably tumours progress to an advanced castrate resistant stage [castration resistant 
prostate cancer (CRPC)]. Mechanisms of progression to CRPC are varied, but a common theme is that AR 
activity is retained and often amplified, despite very low (castrate) levels of circulating androgens. In a cer-
tain percentage of resistant tumours the AR itself is amplified, mutated or truncated, but this is not always 
the case. The AR is a member of the Nuclear receptor (NR) superfamily of transcription factors, and NRs 
share common cofactor proteins which act to increase or decrease their transcriptional activity - known 
as coactivators and corepressors, respectively. These cofactors are frequently multifunctional proteins, and 
AR cofactors include RNA splicing factors such as FUS, cytoplasmic chaperone and co-chaperone proteins 
such as p23 and BAG-1L, cell cycle and transcriptional effectors such as Prohibitin and some CDKs, the 
Hey proteins which are well-characterised Notch effectors, and tripartite motif proteins. We and others 
have shown that amplification of coactivators and loss or dysregulation of corepressors are also mecha-
nisms of therapy resistance in prostate cancer. Interestingly we found that androgen treatment of prostate 
cancer cells results in downregulation of certain corepressors, thus the AR itself may promote tumour 
growth by downregulating its own repressors. Manipulation of AR cofactors is thus a valid therapeutic 
strategy for CRPC, and we have demonstrated that both inhibition of coactivators and increasing levels 
of corepressors can inhibit growth and invasion of prostate cancer cells, in vitro and in vivo. Other factors 
that can affect AR levels and activity are microRNAs, which usually act by reducing levels of their target 
mRNAs. They play vital roles in prostate cancer development, progression and metastasis and we hypoth-
esised that microRNAs that modulate AR activity in lethal CRPC represent novel therapeutic targets for 
this disease. We used a high-throughput functional screen to systematically identify such microRNAs, and 
have shown that microRNAs can affect AR either directly or by targeting key cofactors, including the core-
pressor Prohibitin. Inhibitors of AR-modulatory microRNAs dramatically reduces AR activity and growth, 
migration and invasion of prostate cancer cells, and may thus represent novel prostate cancer therapeutics. 
They also show additive effects with AR silencing or antiandrogen treatment, suggesting potential com-
binatorial applications for prostate cancer treatment. A major advantage of microRNAs is that they are 
released from tumours into the circulation, where they can be detected and quantified. They thus also have 
enormous potential as prognostic and predictive biomarkers.
11.   Tyrosine Phosphorylation of nuclear PTEN in Glioma promotes therapeutic resistance 
        through DNA damage repair
Frank Furnari
Ludwig Institute for Cancer Research, University of California, San Diego, USA
Ionizing radiation (IR) and chemotherapy are standard of care treatments for glioblastoma (GBM) patients 
and both result in DNA damage, however their clinical efficacy is limited due to therapeutic resistance. 
Here, we identified a mechanism of such resistance mediated by nuclear PTEN phosphorylated on tyro-
sine 240 (pY240-PTEN) by FGFR2 kinase. pY240-PTEN is rapidly elevated and bound to chromatin in 
response to IR treatment and facilitates the recruitment of DNA repair protein, RAD51, to sites of damage. 
Thus, cells with high levels of pY240-PTEN are resistant to DNA damage and blocking Y240 phosphoryla-
tion with FGFR inhibitors confers radiation sensitivity to tumors and extends survival in GBM preclinical 
models. The central importance of PTEN Y240 phosphorylation in mediating DNA damage repair is fur-
ther highlighted by the extreme radiation sensitivity of Y240F-PTEN knock-in mice. These results suggest 
that FGFR-mediated phosphorylation of PTEN Y240 is a key mechanism of radiation resistance and is an 
actionable target for improving radiotherapy efficacy in GBM patients.
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12. Understanding and exploiting the hypoxia-induced DNA damage response
Ester Hammond
Oxford Institute for Radiation Oncology, UK
Exposure to severe levels of hypoxia, sometime referred to as radiobiological hypoxia, leads to the induc-
tion of the DNA damage response. As cancer cells in radiobiological hypoxia are significantly more resis-
tant to radiation-induced DNA damage they negatively impact radiotherapy response. The aim of our work 
is to investigate the biological response and adaption by cancer cells to hypoxia, with the ultimate aim of 
developing new therapeutic strategies though the identification of critical molecular targets. Recently, we 
have demonstrated that the hypoxia-induced DNA damage response is a result of replication stress, in part 
due to diminished ribonucleotide reductase activity in the absence of oxygen. Despite the presence of rep-
lication stress and a DNA damage response in hypoxia, we have not observed the accumulation of DNA 
damage. Both the sources of hypoxia-induced replication stress and potential strategies to target this for 
therapeutic gain will be discussed.
13.   Breaking down barriers to tumour immunity
Awen Gallimore
Cardiff University, UK
Whilst certain immunotherapies can drive activation and expansion of tumour-specific T cells, most pa-
tients undergoing these therapies do not exhibit objective responses. A significant bottleneck may be the fail-
ure of activated lymphocytes to infiltrate solid tumours and/or immunosuppressive mechanisms within the 
tumour microenvironment. Foxp3+ regulatory T cells (Treg) often accumulate in solid tumours where they 
help create an immunosuppressive niche. Using a mouse model of carcinogen-induced fibrosarcomas, we 
have examined how Treg depletion impacts on tumour growth. Results of the study show that tumour re-
gression after Treg-depletion is highly variable and observed in only a proportion of animals. Comparing the 
genotype and phenotype of tumours recovered from responder and non-responder mice reveals several key 
features of the tumour microenvironment that distinguish the two groups. These include the type of blood 
vessels present, the composition of the extracellular matrix and the number of tumour infiltrating lympho-
cytes. The reciprocal influences of these features will be discussed as well as the potential for manipulating 
the tumour microenvironment in order to maximise the success of T cell-based immunotherapies.
14.   Combination immunotherapies: aiming at the tumour microenvironment
Gareth Thomas
University of Southampton, UK
Using next generation sequencing and bioinformatic analyses combined with multiplexed immunochem-
istry, we have characterised molecular features of the tumour microenvironment that are associated with 
effective/ineffective anti-cancer immune responses, characterising prognostic/predictive lymphocyte sig-
natures and identifying immune evasion mechanisms that are common across different types of cancer. In 
vivo preclinical testing confirms that specific evasion mechanisms can be targeted to improve response to 
standard immunotherapies, and suggests strategies for combination immunotherapies based on immune 
classification of tumours.
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15.   Chromosomal instability, tumour evolution and treatment resistance
Geoff Macintyre
CRUK Cambridge Institute, Cambridge, UK
Tumours with chromosomal instability exhibit increased intratumoral heterogeneity and poor prognosis. 
Genetically distinct clones enable a wider sampling of the fitness landscape, increasing the chance of rapid 
progression and treatment resistance. Here, I will present our recent work on identifying different types of 
chromosomal instability through copy number signature analysis. I will highlight the role that chromo-
somal instability plays in tumour evolution and the challenges faced trying to move mutational signature 
analysis into the clinic.
16.   Intra-tumour signalling and targeted therapy in melanoma
Claudia Wellbrock
University of Manchester, UK
The BRAF-kinase and the MAPK-pathway are targets of current melanoma therapies, where they can in-
duce fast responses with minimal adverse effects. Our recent work has demonstrated that intra-tumour 
signalling can have a major impact on the efficacy of MAP-kinase pathway targeting drugs. We discov-
ered that the melanoma-specific transcription factor MITF confers cell-autonomous resistance to MAPK 
pathway therapy. Recent work by others has also demonstrated that MITF is an essential survival factor 
for drug-addicted acquired resistant melanomas. We found that during treatment with BRAF and MEK 
inhibitors, MITF expression is up-regulated in responding tumours and as direct consequence of effective 
inhibition of the MAPK pathway. This MITF up-regulation during treatment counteracts the killing-effect 
of the drugs, thus initiating a phase of tolerance to treatment which allows acquired resistance to establish. 
We identified the HIV-protease inhibitor nelfinavir as an inhibitor of the drug-induced MITF up-regula-
tion. In line with this activity, nelfinavir profoundly improves responses to MAP-kinase pathway targeting 
drugs in BRAF and NRAS mutant melanoma. One of the major challenges in tackling acquired resistance 
to MAPK inhibitors is the phenotype heterogeneity found in melanoma. As such melanomas contain sub-
populations of cells that can be described as MITFhigh and MITFlow. We had shown previously that MITF-
phenotype heterogeneity is of advantage for melanoma invasion, but we revealed that it also contributes 
to the establishment of highly resistant tumours. We identified a novel mechanism based on intra-tumour 
communications that maintains phenotype heterogeneity, and targeting this mechanism overcomes het-
erogeneity driven resistance in melanoma.
17.   The NF-κB regulated gene, Claspin, is potential biomarker for the response to Chk1 
        inhibitors
Jill E. Hunter1, Jacqueline A. Butterworth1, Michelle D. Garrett2,3, Ian Collins3, Neil D. Perkins1
1Institute for Cell and Molecular Biosciences, Faculty of Medical Sciences, Newcastle University, Newcastle 
Upon Tyne, Newcastle NE2 4HH, UK
2School of Biosciences, University of Kent, Canterbury CT2 7NJ, UK
3The Institute of Cancer Research, Sutton SM2 5NG, UK
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Disruption of the DNA damage response, frequently seen as a consequence of genetic mutation, can lead 
to more rapid onset of tumorigenesis. However, inhibiting those pathways which are still intact provides a 
potential therapeutic strategy for targeting tumours that have become dependent on their activity. For this 
reason, inhibitors of ATR and Chk1 represent a potential new class of anti-cancer therapies, currently in 
clinical trials. Here, we describe a mechanism, involving the Chk1 targeted phosphosite Thr505 on the NF-
κB subunit, RelA, and how mutation of this site results in earlier onset of MYC-driven lymphomagenesis in 
vivo. We describe a positive feedback loop in which Chk1 phosphorylation of RelA at T505, together with 
the NF-κB subunit c-Rel, drives the expression of the ATR checkpoint kinase regulator Claspin in response 
to DNA replication stress in cancer cells. This in turn is required for maintenance of Chk1 activity. Loss of 
a single allele of the Clspn gene in mice is sufficient to drive earlier tumorigenesis and low levels of CLSPN 
mRNA expression are associated with worse survival in some forms of human cancer. Importantly, disrup-
tion of this pathway leads to resistance of cells to treatment with Chk1 inhibitors, a result with implications 
for the potential use of these drugs as cancer therapies. Taken together, these data suggest that Claspin 
mRNA levels may be a potential biomarker for the response to novel Chk1 inhibitors in the clinic, and also 
a prognostic factor in some cancers. 
18.   Novel strategies to target RNA splicing to overcome androgen receptor splice variant-7 
        signalling in castration resistant prostate cancer
A. Sharp1#, J. C. Welti1#, W. Yuan1, A. Paschalis1, I. Figueiredo1, C. Bertan1, V. S. Gil1, D. N. Ro-
drigues1, E. Knight2, J. Ning2, J. Francis2, D. Dolling1, A. Neeb1, G. Boysen1, M. Crespo1, B. Al-
Lazikani3, S. Carreira1, J. Luo4, A. Swain2, S. R. Plymate5, J. S. de Bono1
1Division of Clinical Studies, The Institute of Cancer Research, UK
2Tumour Profiling Unit, The Institute of Cancer Research, UK
3Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, UK
4Johns Hopkins University School of Medicine, USA
5University of Washington, USA
#The two authors contributed equally to this Abstract
The constitutively active androgen receptor (AR) splice variant-7 (AR-V7) drives persistent AR signalling 
in castration resistant prostate cancer (CRPC). We demonstrate that AR-V7 protein increases as castration 
resistance emerges and associates with resistance to endocrine therapies. In addition, AR-V7 does not cor-
relate with full length AR protein or AR copy number, suggesting that aberrant RNA splicing is critical for 
AR splice variant (AR-SV) generation. Targeting RNA splicing is an attractive strategy to prevent AR-V7 
generation and we demonstrate a novel role of bromodomain and extra-terminal (BET) family protein in-
hibitors in supressing RNA splicing. Our data show that BRD2, BRD3 and BRD4 RNA expression correlate 
with AR driven transcription in CRPC biopsies. Consistent with this, chemical BET inhibition (BETi), and 
BET family protein knockdown, reduced AR-V7 expression and AR signalling in prostate cancer models. 
In addition, we show BETi regulate RNA processing reducing alternative splicing and AR-V7 expression. 
Furthermore, BETi reduce growth of prostate cancer cells and patient derived organoids with known AR 
mutations, AR amplification and AR-V7 expression. Consistent with this, BETi, unlike enzalutamide, de-
creases persistent AR signalling and growth of a patient derived xenograft with AR amplification and AR-
V7 expression. Despite these promising data, the pleotropic effects of BETi on cellular pathways and treat-
ment related toxicities remain a concern. In light of this, we determined critical factors for BETi mediated 
AR-V7 regulation in CRPC. Interrogation of BETi treated RNA expression data and a focused splicing fac-
tor siRNA screen identified splicing factor B (anonymised; Sf-B) crucial for RNA splicing, AR-V7 genera-
tion and PC cell growth. In addition; Sf-B expression correlates with AR signalling and is associated with 
reduced clinical benefit from current endocrine therapies. Based on our results we propose that inhibition 
of Sf-B provides a novel approach to target AR-V7 and other AR-SVs in CRPC. 
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19. Withdrawal of MEK1/2 inhibitor reverses acquired resistance driven by BRAF amplification 
but drives EMT and chemoresistance in cells with amplified KRAS
Matthew J. Sale1, Kathryn Balmanno1, Jayeta Saxena1, Eiko Ozono1, Rebecca E. McIntyre2, 
Katarzyna Wojdyla3, Rebecca Gilley1, Anna Woroniuk1, Karen D. Howarth4, Gareth Hughes5, 
Jonathan R. Dry6, Mark J. Arends7, David Oxley3, Susan Ashton8, David J. Adams2, Julio Saez-
Rodriguez9, Paul D. Smith5, Simon J. Cook1
1Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, UK
2Experimental Cancer Genetics, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cam-
bridgeshire CB10 1SA, UK
3Proteomics Facility, The Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, UK
4Hutchison-MRC Research Centre, Department of Pathology, University of Cambridge, Hills Road, Cam-
bridge CB2 0XZ, UK
5Oncology Bioscience, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, CRUK Cam-
bridge Institute, Robinson Way, Cambridge CB2 0RE, UK
6Oncology Bioscience, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, 35 Gatehouse 
Drive, Waltham, Massachusetts 02451, USA
7Division of Pathology, Centre for Comparative Pathology, Cancer Research UK Edinburgh Centre, MRC In-
stitute of Genetics & Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road 
South, Edinburgh EH4 2XR, UK
8Oncology Bioscience, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Alderley 
Park, Macclesfield SK10 4TG, UK
9European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome 
Campus, Hinxton, Cambridgeshire CB10 1SD, UK
Acquired resistance to MEK1/2 inhibitors can arise through amplification of BRAFV600E or KRASG13D to 
reinstate ERK1/2 signalling. Here we show that BRAFV600E amplification and selumetinib resistance are 
fully reversible following drug withdrawal. Resistant cells with BRAFV600E amplification become addicted to 
selumetinib to maintain a precise level of ERK1/2 signalling (2%-3% of total ERK1/2 active, here quantified 
by mass spectrometry), that is optimal for cell survival and proliferation. The magnitude of ERK1/2 activa-
tion following selumetinib withdrawal (~20% active) drives a p57KIP2-dependent G1 cell cycle arrest and se-
nescence or expression of NOXA and cell death, which selects against those cells with amplified BRAFV600E. 
ERK1/2-dependent p57KIP2 expression is required for loss of BRAFV600E amplification and determines 
the rate of reversal of selumetinib resistance. Furthermore, growth of selumetinib-resistant cells with 
BRAFV600E amplification as tumour xenografts is inhibited in mice that do not receive selumetinib.  Thus, 
BRAFV600E amplification confers a selective disadvantage during drug withdrawal, providing a rationale for 
intermittent dosing to forestall resistance. In striking contrast, selumetinib resistance driven by KRASG13D 
amplification is not reversible. In these cells ERK1/2 reactivation does not inhibit proliferation but drives a 
ZEB1-dependent epithelial-to-mesenchymal transition that increases cell motility and promotes resistance 
to traditional chemotherapy agents arguing strongly against the use of ‘drug holidays’ in cases of KRASG13D 
amplification.
20.   Drug repurposing in neuroblastoma to overcome chemoresistance
Madhu Kollareddy1, Alice Sherard2, Martin Michaelis3, Jindrich Cintal Jr4, Abderrahmane Kaidi2, 
Karim Malik1
1Cancer Epigenetics Laboratory, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK
2Nuclear Dynamics Laboratory, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK
3Centre for Molecular Processing and School of Biosciences, University of Kent, Canterbury, UK
4Institut für Medizinische Virologie, Klinikum der Goethe-Universität, Frankfurt am Main, Germany
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Despite good initial responses towards non-targeted drugs, ~50% of children with high-risk neuroblastoma 
(NB) relapse. Drug-resistance is a major obstacle for successful chemotherapy in high-risk patients. For 
high-risk subset, new chemotherapeutic agents are urgently required for better response and also to com-
bat resistance. We repurposed an Ewing’s sarcoma drug, YK-4-279 (targeted towards EWS-FLI1 oncogenic 
fusion protein) to target ETS-transcription factors (effectors of ALK and Ras-pathways) which are highly 
overexpressed in NB. YK-4-279 inhibited growth of wide range of NB genotypes with different oncogenic 
drivers. Independent of ETS-transcription factors we discovered an unexpected mode of action. YK-4-279 
rapidly induced a strong mitotic phenotype. Depending on the cell line, treatment resulted in multipolar, 
monopolar and fragmented spindles, together leading to disrupted mitotic progression. Notably, YK-4-279 
does not affect microtubule acetylation, unlike the conventional mitotic poisons paclitaxel and vincris-
tine. Mechanistically we show that YK-4-279 affected the distribution of Eg5, a key kinesin involved in the 
fidelity of microtubule assembly. Interestingly YK-4-279 induced robust apoptosis independent of p53 in 
a caspase-3 dependent manner as confirmed by QVD experiments. With respect to mechanism of toxic-
ity our f low cytometry analysis showed that the majority of cells died in subsequent interphase, not in 
mitosis. Strikingly YK-4-279 overcame multi-drug resistance in vincristine resistant NB cell lines. Despite 
extremely high levels of a MDR1/ABCB1 (drug transporter), YK-4-279 was unaffected, suggesting it is not a 
substrate for MDR1 transporter. We also showed that YK-4-279 effectively synergized with clinical mitotic 
inhibitors, highlighting the potential of YK-4-279 as an adjuvant chemotherapeutic agent. Thus, YK-4-279 
could potentially be used as a single-agent or in combination therapies for the treatment of high-risk and 
relapsing neuroblastoma, as well as other cancers.
21.   A potential role for IL6ST mediating endocrine resistance in breast cancer via interaction 
        with the ER signaling pathway
Duniya Mosly1,2, Arran K. Turnbull1,2, Simon P. Langdon1, Andrew H. Sims2
1Cancer Research UK Edinburgh Centre and Division of Pathology Laboratory, MRC 
Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK
2Applied Bioinformatics of Cancer, University of Edinburgh Cancer Research Centre, MRC Institute of Genet-
ics and Molecular Medicine, Edinburgh EH4 2XR, UK
Aim: IL6ST (gp130) receptor has been identified as a predictive biomarker of endocrine treatment response 
in breast cancer patients and is included in the “Endopredict” test. At least seven cytokines signal via 
IL6ST. Interleukin-6 (IL-6) can mediate effects via two signaling pathways; classic signaling (through the 
membrane-bound IL-6 receptor, IL-6R) and trans-signaling (via non-signaling membrane-bound soluble 
IL-6R, sIL-6R). Both pathways may occur in parallel and activate cells.
Methods: Three ERa+ luminal breast cancer cell lines (MCF-7, T47D, ZR-75-1) were chosen to examine 
IL6ST expression by western blot, gel electrophoresis and qRT-PCR. Proliferation assays were carried out 
to investigate the effects of IL-6 family cytokines on cell growth. The action of both IL-6 and OSM on cell 
migration and downstream signaling pathways was studied. The extent of trans-signaling occurrence was 
investigated.
Results: Three cell lines were shown to express varying levels of full length IL6ST. IL6ST soluble forms 
were identified in the three cell lines. Surprisingly, the growth response to the cytokines was variable 
across the cell lines. IL6 caused a modest increase in growth in MCF-7 but produced inhibition in ZR-75-1. 
OSM and LIF stimulated growth in MCF-7, whereas only OSM inhibited ZR-75-1. Interestingly, no signifi-
cant effect on growth was seen in T47D. Both STAT3 and MAPK/ERK pathways were activated to different 
Page 276                                                                               Cancer Drug Resist  2018;1:266-302 I http://dx.doi.org/10.20517/cdr.2018.18
extents in the three cell lines, whereas cells migration was only stimulated in ZR-75-1. The trans-signaling 
pathway significantly enhanced the growth inhibition in ZR-75-1.
Conclusion: The presence of both classic and trans-signaling occurrence in breast cancer cell lines. IL6ST 
full length form is the most abundant form under basal conditions.  The levels of the different IL6ST solu-
ble forms will be further studied after estrogen stimulation. The effect of IL6ST silencing in the presence of 
estrogen and tamoxifen on cell growth and the gene expression is currently being examined.
22.   Computational identification of drug resistance mutations to targeted cancer therapies
Teresa Kaserer, Julian Blagg
Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK
Although targeted cancer therapies have shown great success in the clinic, many patients eventually relapse 
and develop resistance. The underlying mechanisms are often only dissected in clinical studies, leading to a 
reactive approach towards drug resistance. We have developed a computational workflow combining drug 
affinity, clonal fitness and mutational signatures to prioritize resistance mutations in the primary drug 
targets, which are likely to arise upon treatment of a specific cancer type. This workflow has been validated 
on a comprehensive ERK2 benchmark literature dataset and applied to successfully identify clinically-
observed resistance mutations for approved drugs targeting Kit, Abl, EGFR, and ALK. Our results suggest 
that this workflow can be prospectively applied to signpost likely resistance mutations and thereby support 
improved patient monitoring and the timely development of effective next-generation drugs to manage re-
sistance to targeted therapies.
23.   Loss of BAP1 diminishes sensitivity to vinorelbine in Mesothelioma
Anita Singh, Dean A. Fennell, Andrew M. Fry
University of Leicester, University Road, Leicester LE1 7RH, UK
Aim: BRCA1 associated protein 1 (BAP1) is a tumor suppressor that is commonly inactivated in the major-
ity of mesotheliomas. We have previously reported that BRCA1 is lost in 38% of mesothelioma cases and 
leads to vinorelbine resistance. However the mechanism of BRCA1 loss is unknown. Vinorelbine, a spindle 
checkpoint activator that perturbs microtubule dynamics has shown clinical efficacy with a response rate 
of 24%, whereas no other chemotherapeutic agents used in treatment of mesothelioma had a response 
rate greater than 20%. The aim of the study was to explore the functional relationship between BAP1 and 
BRCA1 and their role in vinorelbine resistance.
Methods: We conducted functional analysis of BAP1 and BRCA1 in MSTO (wild-type BAP1), H2452 
(A95D mutation in the UCH domain), and H226 ( BAP1 null cell line) along with expression vectors carry-
ing wild-type or mutant forms of BAP1. BAP1 knockdown was achieved by siRNA transfection in MSTO 
and H2452, while BRCA1 knockdown was achieved by doxycycline induction of an integrated shRNA in 
MSTO.
Results: Loss of BAP1 expression led to reduced expression of BRCA1, whereas knockdown of BRCA1 did 
not affect BAP1 expression. Treatment with the proteasome inhibitor, MG132, restored BRCA1 expres-
sion in the absence of BAP1 indicating that BAP1 contributes to post-translational stabilization of BRCA1 
protein. Loss of BAP1 resulted in vinorelbine resistant, a phenotype similar BRCA1 deficiency. BAP1 also 
promotes BRCA1 foci formation after DNA damage.
Cancer Drug Resist  2018;1:266-302 I http://dx.doi.org/10.20517/cdr.2018.18                                                                          Page 277
Conclusion: Our data demonstrate that BAP1 controls BRCA1 expression through regulating its protein 
stability. Bap1 status is a major determinant of BRCA1 expression and in efficacy microtubule poisons such 
as vinorelbine, a hypothesis that we will test in our randomised Medusa and VIM trial.
24.   Investigating resistance mechanisms to CB-839 in RCC using a genome-wide CRISPR/ 
        Cas9 approach
Aleksandra Raczka
Medical and Biological Sciences Building, University of St Andrews, North Haugh, St Andrews, Fife KY16 
9TF, UK
Renal cell carcinoma (RCC) affects 1 in 82 men and 1 in 57 women, and accounts for about 3% of all can-
cer deaths worldwide. It is characterised by significant tumour heterogeneity and inherent (in 25%-30% 
cases) or acquired resistance to available chemotherapeutics. Most patients who initially respond to treat-
ment develop resistance within 6-15 months. Glutamine addiction is a potential new therapeutic target for 
kidney cancers. These cancer cells use glutamine rather than glucose to meet their enhanced bioenerget-
ics demands to sustain their rapid growth. They are very often deficient in functional von Hippel Lindau 
(VHL) protein, which leads to abnormal accumulation of several proteins involved in angiogenesis and cell 
division. VHL-/- tumours have been recently shown not only to rely on glutamine for energy generation 
and maintenance of redox homeostasis, but also for de novo pyrimidine synthesis. CB-839 is a small, orally 
administered reversible inhibitor of human kidney-type glutaminase (GLS). GLS converts glutamate to 
glutamine and is upregulated in glutamine-addicted cancers, such as RCC and triple negative breast cancer 
(TNBC). CB-839 is currently in clinical trials as a monotherapy and also as part of a combination therapy, 
and shows promising results. Given the significant incidence of resistance to previously approved therapies, 
we are applying a genome-wide CRISPR/Cas9 approach to identify candidate genes, which when knocked 
down will confer resistance to CB-839. We are screening the genome-scale GeCKOv2 sgRNA library, pre-
viously used to identify genes involved in resistance to vemurafenib in melanoma cells. Since most RCCs 
are VHL-/-, we are using 786-O cells as a model of RCC where CB-839 inhibits their growth. This screen 
should identify candidate genes mediating resistance to CB-839 that could be useful as biomarkers or as 
part of rational drug combinations. 
25.   Multivariate variable selection for integrative analysis of cancer drug data
Jian Zhang, Elaheh Oftadeh
School of Mathematics, Statistics and Actuarial Science, University of Kent, Canterbury CT2 7FS, UK
Cancer drugs exert their function through binding to one or more protein targets (Wang et al., 2014). Early 
“one gene, one drug, one cancer” paradigm considers the role of individual genes and their changes in 
drug-perturbed states, which largely ignore a target’s cellular and physiological context. Meanwhile, can-
cer gene-centric methods largely ignore the multi-factor-driven attribute of cancer diseases at the cellular 
level. With the generation of rich data resources for genome-wide gene expressions and drug- and cancer-
induced perturbations, we propose an integrative analysis of these data to provide systematic insights 
into mechanisms of drugs and cancers in a “multiple genes, multiple drugs, multiple types of cancers” 
paradigm. The proposed method, called principal variable analysis, aims at selecting predictor variables 
with relatively higher coefficient variations in a multivariate regression model. The basic premise behind 
the proposal is to scan through a predictor variable space with a series of forward filters named null-
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beamformers; each is tailored to a particular region in the space and resistant to interference effects origi-
nating from other regions. The new approach attempts to explore the maximum amount of variation in the 
data with a small number of principal variables. Through simulation studies, we show that it substantially 
outperforms the existing methods in terms of sensitivity and specificity. We apply the proposed method 
to IC50 cancer drug and gene expression datasets, identifying a set of important genes co-associated with a 
group of cancer drugs.
26.   Targeting of a transcriptional state implicated in resistance to MEK inhibition in KRAS-
        mutant colorectal cancer
Steve Wagner1, Georgios Vlachogiannis2, Alexis De Haven Brandon1, Melanie Valenti1, Gary 
Box1, Liam Jenkins3, Caterina Mancusi1, Annette Self1, Floriana Manodoro4, Ioannis Assiotis4, 
Penny Robinson4, Ritika Chauhan4, Alistair G Rust4, Nik Matthews4, Kate Eason2, Khurum 
Khan5, Naureen Starling5, David Cunningham5, Anguraj Sadanandam2, Clare M. Isacke3, Vladimir 
Kirkin1, Nicola Valeri2,5, Steven R. Whittaker1
1Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK
2Division of Molecular Pathology, The Institute of Cancer Research, London, UK
3Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK
4Tumour Profiling Unit, The Institute of Cancer Research, London, UK
5Department of Medicine, Royal Marsden NHS Foundation Trust, London, UK
The MEK inhibitor (MEKi) trametinib has shown clinical benefit in BRAF-mutant melanoma but showed 
no clinical responses in KRAS-mutant colorectal cancer. To gain insight into potential mechanisms of 
resistance, we used a pharmacogenomics analysis of colorectal cancer cell lines exhibiting differential sen-
sitivity to MEK inhibition. Strikingly, we identified a transcriptional state, involving increased interferon 
and inflammatory gene expression, to be highly enriched in cell lines displaying intrinsic and acquired 
resistance to MEK inhibition. Inhibition of this transcriptional state was achieved by small molecule inhi-
bition of the bromodomain family of proteins, which suppressed interferon and inflammatory gene expres-
sion and restored sensitivity to MEK inhibition. The combination of the bromodomain inhibitor JQ1 and 
trametinib showed synergistic anti-proliferative effects and induced apoptosis in MEKi-resistant colorectal 
cancer cell lines. Elevated expression of interferon/inflammatory genes was observed in patient-derived or-
ganoid models which were also resistant to trametinib and were resensitized by co-treatment with JQ1. In 
both xenograft and syngeneic models of colorectal cancer, the combination of trametinib and JQ1 signifi-
cantly suppressed tumour growth compared to either agent alone. Furthermore, using a 66-gene signature 
we found that high expression of interferon/inflammatory genes was associated with significantly reduced 
survival of colorectal cancer patients. These findings provide a novel explanation for the lack of response 
to MEK inhibitors in KRAS-mutant colorectal cancer, known for its inflammatory nature. Importantly, we 
have identified a novel therapeutic strategy to overcome both intrinsic and acquired resistance to MEK in-
hibition in colorectal cancer. 
27.   A genome-wide CRISPR screen to identify combination strategies for AZD5353 (AKTi) and 
        AZD8186 (PI3Kβi) in PTEN-null breast cancer
Shanade Dunn1,4, Jason Yu4, Swee Hoe Ong4, Yan Zi Au4, Urs Yelland2, Natalie Cureton2, Anna 
Staniszewsla1, James Pilling3, Philip Hopcroft3, Beverley Isherwood3, Simon Barry1, Barry Da-
vies1, James Lynch1, Kosuke Yusa4
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1Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK
2Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Alderley Park, UK
3Discovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, UK
4Wellcome Trust Sanger Institute, Cambridge, UK
The PI3K-AKT-mTOR pathway is frequently hyper-activated in breast cancer and several inhibitors tar-
geting the PI3K pathway, including AKT (AZD5363) and PI3Kβ (AZD8186), are in clinical development. 
A better understanding of the mechanisms of resistance to PI3K pathway inhibitors is critical for the 
development of combination strategies. To this end, we performed genome-wide CRISPR-Cas9 knock-
out screens to identify genes that mediate drug resistance to AZD5363 and AZD8186 in three PTEN-null 
breast cancer cell lines. The screens have confirmed a number of known resistance genes and also revealed 
a number of novel mediators. Moreover, our screens identified a number of “sensitiser” genes. Eighteen of 
these hits have inhibitors in clinical development and we have performed a combination screen to identify 
the compounds that give the best synergy with AZD5363/AZD8186 across the breast cancer cell lines. The 
most striking combination was with the Mcl-1 inhibitor, AZD5991. Mechanistic work is ongoing and our 
data suggest that AZD5363/AZD8186 “prime” cells for apoptosis and combined inhibition with AZD5991 
drives a rapid apoptotic response. Furthermore, these combinations induce regressions in a breast cancer 
xenograft model. Overall, our CRISPR screening data provide new insights into the pathways that drive 
resistance and have identified novel synergistic combinations.
 
28.   Acquired resistance mechanisms to β-tubulin inhibitors in triple negative breast cancer
Helen E. Grimsley1, Jindrich Cinatl Jr2, Catherine Harper-Wynne3, Karina Cox3, Martin 
Michaelis1, Mark N. Wass1, Michelle D. Garrett1
1School of Biosciences, University of Kent, Canterbury, UK
2Institut für Medizinische Virologie, Klinikum der Goethe-Universität, Frankfurt am Main, Germany
3Maidstone and Tunbridge Wells NHS Trust
Microtubules are dynamic components of the cytoskeleton, and are common targets for anticancer thera-
pies. Disruption of mitotic processes through inhibition of β-tubulin, an essential building block of the 
mitotic spindle, leads to mitotic catastrophe. β-tubulin inhibitors; Eribulin and Paclitaxel are common 
drugs for the treatment of triple negative breast cancer. Triple negative breast cancer exhibits an aggressive 
metastatic phenotype and patients are commonly known to relapse due to acquired drug resistance. Here 
we start to elucidate mechanisms of resistance to β-tubulin inhibitors which may provide opportunities to 
strategically alter their therapeutic use in patients. In vitro assays demonstrated similar phenotypes in the 
Eribulin-adapted and Paclitaxel-adapted cell lines, distinct from the parental. Cross-resistance was found 
upon treatment with Eribulin and Paclitaxel in the drug-adapted cell lines. Remarkably, whole exome se-
quencing analysis showed only a small number of variants gained in the drug-adapted cell lines, with even 
less shared in respective drug-adapted cell lines. Our results suggest that although similar responses in the 
drug-adapted cell lines are seen when treated with Eribulin and Paclitaxel, the acquired resistance mecha-
nisms are most likely to be different. 
29.   The role of SOX4 in drug-resistant chronic myeloid leukemia
Jorge Luis Jimenez Macias, April J. Baral, Peter Laslo
Section of Experimental Haematology, Leeds Institute of Molecular Medicine, St James’s University Hospital, 
Leeds, UK
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Chronic myeloid leukaemia (CML) is associated with the BCR-ABL1 (BA) oncogene and managed with 
drug therapy [Imatinib (IM)]. However, 20% of patients will develop drug resistance resulting in fatality 
within 12 months. Previous work in the lab had established a preclinical model of CML drug resistance 
using KCL22 cells. By gradually exposing these cells to increasing concentrations of IM, a drug-resistant 
derivative (IMr) was established. The IMr cells recapitulated clinical observations where drug treatment 
ablated the activity of BA yet they continue to grow. In order to survive the IMr cells must acquire new 
oncogenic drivers that compensate for the loss of BA. Research focused on the functional requirement 
of the SOX4 factor in establishing the IMr phenotype. Depletion of SOX4 within the IMr cells inhibited 
cell growth. Interestingly, the complimentary gain-of-function studies failed to generate SOX4-expressing 
KCL22 stables. Targeting SOX4 with the aim of restoring its normal functional activity holds great promise 
for the therapeutic treatment of drug-resistant CML. 
30.   PHLDA1 downregulation mediates drug resistance in receptor tyrosine kinase-driven 
        cancer and can be modulated using HDAC Inhibitors
N. S. Clayton1, E. P. Carter1, A. E. Fearon2, J. A. Heward3, R. P. Grose1
1Centre for Tumour Biology, Barts Cancer Institute - a CRUK Centre of Excellence, Queen Mary University of 
London, London EC1M 6BQ, London, UK
2Inst. f. Molecular Health Sciences, Department of Biology, ETH Zürich, Zürich 8093, Switzerland
3Centre for Haemato-Oncology, Barts Cancer Institute, London EC1M 6BQ, UK
Development of resistance causes failure of drugs targeting oncogenic receptor tyrosine kinases (RTKs) 
and represents a critical challenge for precision medicine. Here, we show that transcriptional downregula-
tion of the PH domain-containing protein PHLDA1 is critical to the acquisition and maintenance of drug 
resistance in RTK-driven cancer. Using resistance to fibroblast growth factor receptor - targeted therapy 
as a model, we identified an Akt-driven compensatory mechanism underpinned by downregulation of 
PHLDA1. We demonstrate broad clinical relevance of our findings, showing that PHLDA1 downregulation 
also occurs in response to RTK-targeted therapy in breast and renal cancer patients. Crucially, knockdown 
of PHLDA1 alone was sufficient to confer de novo resistance to RTK inhibitors in vitro and induction of 
PHLDA1 expression re-sensitized drug-resistant cancer cells to targeted therapies. This identifies PHLDA1 
as a biomarker for drug response and highlights the potential of PHLDA1 reactivation as a means of cir-
cumventing resistance to RTK inhibitors. We have identified inhibition of the MAPK pathway as a crucial 
step in PHLDA1 downregulation and show that ERK1/2 inhibition produces significant epigenetic changes 
at the PHLDA1 locus, specifically, a decrease in the activatory marks H3Kme3 and H3K27ac. In line with 
this, we show that treatment with clinically relevant Class I HDAC inhibitors restores PHLDA1 expression 
in resistant cells. Using HER2+ breast cancer cells as a model system, we have shown that HDAC inhibitors 
increase the sensitivity of resistant cells to HER2+-targeted therapy and when given in combination with 
lapatinib, produce a synergistic effect on cell growth in parental cell populations. 
31.   Elucidating mechanisms of resistance to PI3K inhibition in pancreatic cancer using 
        functional genomics and combinatorial drug screening
Charlotte Milton1, Annette Self1, Rosemary Burke1, Federica Piccioni2, David Root2, Steven R. 
Whittaker1
1Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK
2Genetic Perturbation Platform, The Broad Institute, Cambridge, MA, USA
Activating mutations in the oncogene KRAS are present in 95% of pancreatic ductal adenocarcinoma 
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(PDAC) and drive tumorigenesis and disease progression. The PI3K pathway is activated downstream of 
oncogenic KRAS signalling and presents an attractive therapeutic target for the treatment of this lethal 
disease. However, when tested in PDAC clinical trials, PI3K pathway inhibitors have thus far derived no 
significant benefit. We hypothesise that an adaptive response mediates resistance to PI3K inhibition in 
PDAC, targeting of which may present a novel therapeutic strategy. We found that resistance to the PI3K 
alpha inhibitor, BYL719, is associated with sustained PI3K-independent activation of mTORC1 in a panel of 
PDAC cell lines. We demonstrate that inhibition of mTOR, in combination with PI3K inhibition, is neces-
sary to fully supress PI3K signalling and inhibit proliferation of PDAC cells. Through genome-scale and 
focussed, mini-pool CRISPR screens, we nominated key genes in the mTOR and RTK signalling networks 
responsible for mediating resistance and show that siRNA mediated knockdown of these genes is sufficient 
to sensitise to PI3K alpha inhibition in multiple cell lines. Notably, over-expression of multiple genes in-
volved in determining PI3K inhibitor sensitivity is associated with significantly decreased patient survival. 
Targeting of multiple nodes in the PI3K signalling network is therefore essential to overcoming resistance 
to single agent PI3K alpha inhibition. In 3D stromal co-culture models, inhibition of either mTOR, EGFR 
or PDK1 synergistically inhibited spheroid growth in combination with PI3K alpha inhibition. Our work 
therefore supports further investigation into combined PI3K and RTK inhibition for the treatment of pan-
creatic cancer. 
32. A predictive model of “on-target” drug resistance (for poster)
Daniel O’Neill1,3, Maryam Clausen2, Mike Firth1, Jonathan Wrigley1, Maria Emanuela Cuomo1
1AstraZeneca, IMED Discovery Sciences, Cambridge, UK
2AstraZeneca, IMED Discovery Sciences, Gothenburg, SE
3AstraZeneca, IMED Oncology, Cambridge, UK
Acquired drug resistance represents a major challenge in the development of therapeutic agents for the 
treatment of cancer. The problem is exemplified by non-small cell lung cancer (NSCLC) containing activat-
ing EGFR mutations. NSCLC tumours driven by EGFR variants are initially sensitive to tyrosine kinase 
inhibitors (TKI), but some patients show renewed disease progression through expansion of tumour cell 
clones harbouring additional EGFR mutations. Models of drug resistance are therefore necessary to in-
crease our understanding of resistance mechanisms, predict variants that will arise in patients and improve 
drug development strategies. In the past, this problem has been addressed by screening large panels of gene 
variants for drug resistance phenotypes in cell culture. Previous methods such as chemical mutagenesis 
has the advantage of testing mutations genome wide but did not cover all possible amino acid variants 
in a specific region of interest. On the other hand, saturation mutagenesis with “on target” cDNA librar-
ies resulted in expression of all possible variants but in a non-physiological setting, detached from their 
endogenous regulatory mechanisms. For the first time, CRISPR/Cas9 allows endogenous modification of 
genes and facilitates introduction of all possible mutations at a specific locus, whilst maintaining endog-
enous gene architecture, chromosomal context and epigenetic mileu. Here we describe the novel CRISPR-
based methodology targeted endogenous mapping of pharmacological resistance developed to identify “on 
target” mutations in key oncogenes that drive pharmacological resistance. Using EGFR as a target, we show 
how directed evolution of some residues in the EGFR kinase domain can be predictive of the resistance 
observed in the clinic in response to known TKIs, such as gefitinib and osimertinib. In fact, in the region 
analysed, we can recapitulate the variants observed clinically. We also identify amino acids chemically and 
structurally able to confer resistance to a TKI in structurally conserved tyrosine kinases such as BCR-Abl 
and Kit.
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33.   A FGF7-FGFR2 autocrine loop maintains fusion positive rhabdomyosarcoma cell growth 
        and is associated with preclinical efficacy of the FGFR inhibitor NVP-BGJ398
Christopher I. Milton1, Joanna Selfe1, Edoardo Missiaglia2, Ewa Aladowicz1, Zoë S. Walters1, Su-
sanne A. Gatz1, Melanie Generali6, Gary Box3, Melanie Valenti3, Alexis de Haven-Brandon3, Da-
vid Galiwango4, Angela Hayes4, Matthew Clarke5, Elisa Izquierdo5, David Gonzalez De Castro6, 
Florence Raynaud4, Suzanne Eccles3, Janet M. Shipley1 
1Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Insti-
tute of Cancer Research, London, UK
2Department of Molecular Pathology, Centre Hospitalier Universitaire Vaudois, Lausanne CH-1011, Switzer-
land
3Tumour Biology and Metastasis Team, Division of Cancer Therapeutics, The Institute of Cancer Research, 
London, UK
4Drug Metabolism and Pharmacokinetics Team, Division of Cancer Therapeutics, The Institute of Cancer Re-
search, London, UK
5Glioma Team, Division of Molecular Pathology, The Institute of Cancer Research, London, UK
6Molecular Haematology, Division of Molecular Pathology, The Institute of Cancer Research, London, UK; 
current address for Melanie Generali: Center for Therapy Development (GMP), Institute for Regenerative 
Medicine (IREM), University of Zurich, Zurich CH-8044, Switzerland; and current address for David Gonza-
lez De Castro: School of Medicine, Dentistry and Biomedical sciences, Queens University Belfast, Belfast BT9 
7BL, UK
Rhabdomyosarcoma (RMS) is the most common form of soft tissue sarcoma in children. Patients whose 
tumours harbour a genetic fusion, the most common of which is PAX3-FOXO1, carry the worst prognosis 
with a 5-year survival rate of less than 30%. Evidence demonstrates that fibroblast growth factor receptor 
4 (FGFR4) plays a role in fusion positive RMS cell growth, although it is not clear whether other family 
members (FGFRs 1-3) contribute as well. We sought to validate FGFR involvement in RMS proliferation 
and to provide preclinical evidence that inhibiting FGFR signalling is a viable therapeutic strategy in this 
tumour type. From a RMS cell line screen we identified fusion positive cells as more sensitive than fu-
sion negative cells to the FGFR inhibitor and clinical candidate NVP-BGJ398. Sensitivity correlated with 
high mRNA expression of FGFR2 and its specific ligand FGF7. Genetic knockdown of FGF7 and FGFR2 
decreased fusion positive but not fusion negative RMS cell viability. Interestingly, levels of secreted FGF7 
protein were maintained alongside FGFR signalling through the MAPK pathway upon serum starvation. 
This indicates that fusion positive RMS growth in vitro is sustained by a FGF7-FGFR2 autocrine loop. We 
mined expression data from three independent RMS patient cohorts which revealed overexpression of 
FGFR2 and FGF7 in fusion positive tumours compared to fusion negative tumours and normal muscle. 
Oral administration of NVP-BGJ398 to immunodeficient mice, at doses within the range achievable in 
humans, significantly inhibited fusion positive RMS01 and RH41 xenograft tumour growth, concomitant 
with diminished FGFR/MAPK signalling and a lower proliferative index. Finally, using clonogenic assays 
in vitro we demonstrate that NVP-BGJ398 is synergistic in combination with Irinotecan, a chemotherapeu-
tic used in the standard treatment of RMS patients. Together these data suggest that NVP-BGJ398 is an at-
tractive therapeutic option, particularly in combination with Irinotecan, for high-risk fusion positive RMS 
patients.
34. Exploring resistance of renal cell carcinoma to targeted therapy 
Hossam M. Kamli1,2, Li Li3, David A. Vesey1,4, Glenda C. Gobe1,5
1University of Queensland Princess Alexandra Hospital Kidney Disease Research Collaborative, Translational 
Research Institute, Brisbane, Queensland, Australia
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2Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, 
Abha, Saudi Arabia
3UQ-Ochsner Clinical School, Ochsner Clinic Foundation, New Orleans, LA, USA
4Departments of Urology and Nephrology, Princess Alexandra Hospital, Woolloongabba, Brisbane, Australia
5UQ NHMRC CKD.QLD CRE, Royal Brisbane and Women’s Hospital, Brisbane, Australia
Renal cell carcinoma (RCC) accounts for 2%-3% of all adult malignancies and its incidence has risen over 
past decades. If untreated, RCC is associated with high rates of metastasis and high mortality, partially 
due to high levels of drug resistance. The novel gold-standard tyrosine kinase inhibitor, Sunitinib, targets 
angiogenesis and other multiple pathways in RCC treatment. Sunitinib-resistance is a major clinical prob-
lem for treatment of RCC. The comprehensive characterisation of morphological, functional and molecular 
changes in Sunitinib-resistant RCC cells is lacking. We aimed to develop Sunitinib-resistant human RCC 
cell lines (SN12K1, Caki-1, Caki-2 and 786-0) and characterise the cellular biological changes. RCC cells 
were made resistant by continuous, chronic exposure to 10 µmol/L Sunitinib. Resistant RCC cell lines were 
stable in 10 µmol/L Sunitinib for nearly 2 years, while in parental cell lines, 10 µmol/L Sunitinib induced 
95%-98% cell death at 72-h. Cell proliferation, morphology, transmigration, a cellular adhesion assay, and 
gene expression (Q-RT-PCR) for vascular endothelial growth factor (VEGF), interleukin (IL)-6, IL-8, Bcl-
2 and Bax were studied. There was no significant difference in growth rate and transmigration between 
the parental and resistant cells. Sunitinib-resistant cells were significantly hypertrophic compared with 
parental cells as evidenced by increases in the surface areas of the whole cells and the nuclei. VEGF was in-
creased in Caki-2 and SN12K1 resistant cells by 5 and 2-fold, respectively. IL-6 was increased significantly 
in 786-0, Caki-1, Caki-2 and SN12K1 resistant cells by 3.5, 2, 2 and 12-fold, respectively. IL-8 increased in 
Sunitinib-resistant Caki-2 and SN12K1 cells by 2 and 2.5-fold, respectively. The Bcl2/Bax ratio increased 
in Caki-1, Caki-2, and SN12K1 cells by 1.5, 2, and 2-fold, respectively, indicating increased apoptosis resis-
tance. Elevated IL-6 may contribute to Sunitinib resistance either via VEGF-mediated angiogenesis or anti-
apoptotic Bcl2. Thus inhibition of IL-6 could be a promising way to overcome drug resistance.
35.    PEA-15 unphosphorylated at both serine 104 and serine 116 sensitizes ovarian carcinoma 
         cells to cisplatin 
Shahana Dilruba1, Anke C. Schiedel2, Naoto T. Ueno3, Florian Rothweiler4, Jindrich Cinatl Jr4, 
Martin Michaelis5, Ganna V. Kalayda1
1Institute of Pharmacy, Clinical Pharmacy, University of Bonn, Germany
2Institute of Pharmacy, Pharmaceutical Chemistry I, University of Bonn, Germany
3Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, 
TX, USA
4Institute of Medical Virology, Goethe University Hospital Frankfurt, Frankfurt/Main, Germany
5Industrial Biotechnology Centre and School of Biosciences, School of Biosciences, University of Kent, Canter-
bury, UK
Cisplatin belongs to the standard chemotherapy regimens of various solid tumors. extracellular signal-
regulated kinase 1 and 2 (ERK1/2) is activated following cisplatin treatment. Upon activation, ERK1/2 
shuttles between different cellular compartments, where it acts on various targets. Intracellular traffick-
ing of ERK1/2 is regulated, among others, by a small scaffold protein PEA-15 (phosphoprotein enriched in 
astrocytes-15kDa). Depending on its phosphorylation at serine 104 and serine 116, PEA-15 can sequester 
ERK1/2 in the cytoplasm or facilitate its nuclear translocation. In addition, PEA-15 mediates other cellular 
processes such as autophagy and apoptosis. These functions of PEA-15 have also controlled its phosphory-
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lation status. Here we have investigated the hypothesis that, depending on the phosphorylation state, PEA-
15 can enhance cisplatin sensitivity in ovarian cancer cells. Two mutated versions of PEA-15 mimicking 
the two phosphorylation statuses of the protein were overexpressed in SKOV-3 human ovarian carcinoma 
cells by Lipofectamine-mediated transfection. PEA-15AA is a mutated non-phosphorylatable form of PEA-
15 capable of ERK1/2 binding in the cytoplasm, whereas PEA-15DD is a phosphomimetic variant stimulat-
ing ERK1/2 nuclear translocation. PEA-15AA overexpression resulted in a significant increase (P < 0.0001) 
in cisplatin sensitivity (EC50 = 10.0 µmol/L) compared to the mock-transfected cells (EC50 = 14.9 µmol/L) as 
determined by an MTT-assay. In PEA-15DD-transfected cells, cisplatin cytotoxicity (EC50 = 14.3 µmol/L) 
was similar to that of the mock-transfected controls. The whole-transcriptome expression profiling with a 
ClariomTM S microarray revealed the Nrf2/ARE signaling pathway as central to the PEA-15AA positive ef-
fect on the sensitivity of SKOV-3 cells to cisplatin. The relevance of this pathway was successfully validated 
using retinoic acid, which is a potent inhibitor of Nrf2/ARE. Co-treatment with 20 µmol/L retinoic acid 
significantly (P < 0.0001) sensitized SKOV-3 cells to cisplatin as EC50 was reduced from 32.6 µmol/L for the 
platinum complex alone to 14.0 µmol/L in the combination. Our results show that non-phosphorylatable 
PEA-15 increases cisplatin sensitivity in SKOV-3 human ovarian carcinoma cells through interference with 
the Nrf2/ARE signaling.
36.   Identifying a potential role for TauT in conferring resistance to standard treatment in glio
        blastoma 
Nora Rippaus1, Julie Higgins1, Rhiannon Barrow1, Alexander Bruns1, Aruna Chakrabarty2, 
Azzam Ismail2, Jacquelyn Bond1, Katherine Ashton3, Khaja Syed4, Michael Jenkinson4,5, Andrew 
Brodbelt4, Susan Short1, Lucy F. Stead1
1Faculty of Medicine and Health, St James’s University Hospital, University of Leeds, Leeds LS9 7TF, UK
2Leeds Teaching Hospitals NHS Trust, St James’s University Hospital, Leeds LS9 7TF, UK
3Lancashire Teaching Hospitals NHS Trust, Royal Preston Hospital, Preston PR2 9HT, UK
4Walton Centre NHS Trust, Liverpool L9 7LJ, UK
5Institute of Translational Medicine, University of Liverpool, Liverpool L9 7LJ, UK
Glioblastoma (GBM) is an incurable and fatal brain cancer; almost half of patients die within a year of di-
agnosis despite a standard, aggressive treatment regimen of surgery, radiotherapy and chemotherapy with 
Temozolomide. All drugs designed to target molecular features of primary GBM tumours have failed to 
prolong survival. This is likely because of inherently treatment-resistant cells within primary tumours that 
evade current therapies, continuing to proliferate to form a recurrent tumour. We have sequenced RNA 
from paired pre- and post-treatment GBM patient tumours to identify genes that are differentially ex-
pressed between primary and recurrent GBMs and investigate whether treatment resistance is driven at the 
transcriptional rather than genomic level, as suggested from recent published work. In parallel, we isolated 
cancer cells from a newly resected primary GBM and cultured them as polyclonal spheroids in stem-cell 
permissive conditions. Half of these spheroids received the non-surgical components of standard treat-
ment and seven days later we sequenced RNA from single cells from both treated and untreated spheroids. 
SLC6A6 was the most significantly upregulated gene in recurrent vs. matched primary patient tumours 
and the only gene that was also significantly upregulated in treated vs. untreated single cells. One inter-
pretation of these data is that GBM cells expressing SLC6A6 are more resistant to standard treatment. This 
is supported by: (1) the fact that patients with primary GBM tumours with low SLC6A6 expression have 
significantly better prognosis; (2) work showing that SLC6A6 expression promotes multidrug resistance 
in colorectal cancer; (3) preliminary data from functional screens that we have performed on established 
GBM cell lines. SLC6A6 encodes a taurine transporter, TauT, with an important role in brain development 
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for which we postulate a mechanism for conferring treatment resistance in GBM, the testing of which is 
the focus of our ongoing work.
37.   Single-cell analysis of cancer-associated fibroblast heterogeneity in non-small cell lung 
        cancer: mapping molecular phenotypes in tumours 
Sara Waise, Rachel Parker, Matthew Rose-Zerilli, Christian Ottemsmeier, Christopher Hanley#, 
Gareth Thomas#
Cancer Sciences Unit, Somers Building, University of Southampton, Tremona Road, Southampton SO16 6YD, UK
#The two authors contributed equally to this Abstract
Aim: To characterise the heterogeneity and spatial relationships of the cancer-associated fibroblast (CAF) 
population in non-small cell lung cancer. 
Methods: Fresh primary lung tissue was dissociated to extract the maximum possible proportion of CAF 
(using collagenase P for sixty minutes). Single-cell RNA sequencing was performed using a droplet-barcod-
ed sequencing platform. Bioinformatic analysis was carried out in R, with cell type identification and gene 
set enrichment using the ToppFun tool and GSEA program. Spatial relationships between cell types were 
characterised using a multi-immunohistochemical staining protocol.
Results: Analysis of 12 non-small cell lung cancer (NSCLC) tumours and 6 matched non-involved lung 
samples revealed the presence of 5 CAF subtypes. Three subgroups showed transcriptomic overlap with 
normal fibroblasts. Of the distinct CAF populations, one showed enrichment and expression of genes as-
sociated with the ‘myofibroblastic’ CAF phenotype. The second CAF cluster showed higher expression of 
growth factors and immune cell exclusion on histology. Multiplexed IHC using identified cluster markers 
demonstrated that these subtypes have different spatial distribution and relationships to other cell types. 
Of the remaining three subtypes, one showed gene expression and enrichment consistent with the previ-
ously-described ‘inflammatory’ fibroblast subtype. The remaining two clusters show significant prognostic 
impact, but their functions have yet to be elucidated. 
Conclusion: Despite their abundance in most solid cancers, CAF remain a poorly-characterised population. 
No single marker reliably identifies all CAF and is not yet clear whether distinct CAF phenotypes exist or 
whether such subgroups have different functions. We have identified six stromal populations in NSCLC. 
The fibroblast subtypes show differential gene set enrichment, spatial distribution and prognostic impact, 
suggestive of functional differences. Clinical trials of stromal targeting agents have so far shown disap-
pointing results: identification of pro-malignant CAF subgroups may facilitate the development of more 
specific strategies.
38.   The unfolded protein response in prostate cancer: developing novel strategies for 
        therapeutic intervention
Ana Maria Isac, Filippo Prischi, Philip Reeves, Greg Brooke
School of Biological Sciences, University of Essex, Colchester, UK
Prostate cancer (PCa) cells grow in an environment which is known to cause endoplasmic reticulum (ER) 
stress. This leads to the activation of a process called the unfolded protein response (UPR) which tumour 
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cells can utilise to survive and adapt to their adverse environmental conditions. Importantly, the UPR has 
also been shown to be directly regulated by the androgen receptor, linking the UPR to the key oncogenic 
driver of PCa. The aim of this project is to characterise UPR in PCa and to identify methods to target this 
pathway and promote tumour death. In order to mimic the stressful conditions of the tumour microenvi-
ronment, Tunicamycin - a natural occurring antibiotic, was used to induce ER stress in four PCa cell lines 
representing different stages of the disease (BPH-1, LNCaP, DU145 and PC3). Proliferation, as well as flow 
cytometry assays, were used to study the effects of ER stress upon PCa cell proliferation, cell cycle and cell 
death. Additionally, q-PCR analysis of downs-stream target genes was used to study the activation of the 
UPR in response to ER stress. It has been found that ER stress reduces the proliferation of all PCa cells and 
induces apoptosis. However, each cell line had a different sensitivity to ER stress. LNCaP cells were found 
to be the most sensitive, having all three UPR arms active after 6 h of stress and displaying G1 cell cycle ar-
rest as well as high levels of apoptosis. DU145 had the highest apoptotic levels and the IRE1α arm activated 
after 24 h of stress. BPH-1 and PC3 were less sensitive to ER stress, with BPH-1 having the lowest apoptotic 
levels and no UPR arms being activated in PC3 after 24 h of stress. Further research will investigate the 
effects of anti-androgens upon UPR signalling and characterise UPR target gene expression in response to 
Tunicamycin and UPR inhibitors. Finally, UPR signalling will be manipulated in order to identify novel 
therapeutic methods to treat therapy resistant disease.      
39. Non-natural Macromolecules for new therapeutic strategies
Saeed Akkad1, Michelle D. Garrett2, Christopher J. Serpell1
1School of Physical Sciences, University of Kent, Canterbury, Kent CT2 7NH, UK
2School of Biosciences, University of Kent, Canterbury, Kent CT2 7NJ, UK
At the heart of biology are macromolecules with high-precision architectures - proteins and nucleic acids - 
which are integral to all processes of life. Medicine can be viewed as a mission to modulate the activity of 
these polymers. Historically, this has been achieved mainly using small molecules which bind to a specific 
region of a biomacromolecule. However, biochemistry is replete with macromolecule-on-macromolecule 
processes, pointing to alternative therapeutic strategies. To some extent this is reflected in the rise of bio-
pharmaceuticals (biologics) as medicines, but this neglects the potentially much greater chemical space 
that is possible using non-natural macromolecules. Such species could be more highly tailored for certain 
purposes, possess a much greater range of functionalities, be tuned for localisation, degradation, and im-
munogenicity, and could be made in scalable processes as used for other chemical entities. We are using 
precision macromolecules to address cancer in two ways. In the first case, we are working to make the che-
mopreventive effects of non-steroidal anti-inflammatory drugs such as aspirin useful by creating nanocar-
riers which will direct them solely to cancer tissues. In the second approach, we are using a novel method 
to generate sequence-defined non-natural polymers which undergo programmed folding and self-assembly, 
analogous to proteins. These precision macromolecules are candidates for modulation of the most chal-
lenging oncogenic protein-protein interactions such as the RAS-RAF and MYC-MAX pairs. We are devel-
oping a chemical evolution strategy to identify binders of these proteins.
40.   A combination of CDK4/6 and IGF-IR inhibitors induces synergistic growth inhibition of 
        human colorectal cancer cells with acquired resistance to anti-EGFR antibody
S. A. Khelwatty1, S. Essapen1,2, A. M. Seddon1, Z. Fan3, H. Modjtahedi1
1Kingston University London, School of Life Science, London, UK
2Royal Surrey County Hospital, St Luke’s Cancer Centre, Guildford, UK
3Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, 
TX, USA
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Acquired-resistance to anti-EGFR monoclonal antibodies (mAbs) is a major cause of treatment failure in 
patients with colorectal cancer (CRC), highlighting the need for more effective therapeutic strategies in 
such patients. We have previously shown that acquired-resistance to anti-EGFR mAb ICR62 in DiFi CRC 
cells (DiFi62) is accompanied by an increased EGFR expression, and augmented HER-2/HER-3 signalling 
and sensitivity to the pan-HER blocker afatinib. In this study, we investigated the therapeutic potential 
of the CDK inhibitors (palbociclib and ribociclib) as a single agent or in combination with the IGF-IR 
inhibitors (NVP-AEW541, NVP-ADW742) or MEK inhibitor (trametinib) in parental DiFi cells and their 
resistant varaints. The ICR62 resistant varaint was found to be highly resistant to treatment with palbo-
ciclib and trametinib. Interestingly, the gefitinib resistant DiFiG cells were found to be sensitive to NVP-
AEW541, NVP-ADW742, ribociclib, palbociclib and trametinib. While the combination of CDK inhibitors 
with NVP-AEW541 yielded synergistic growth inhibition in DiFi62 cells, the same combination was an-
tagonistic in DiFiG cells. In addition, trametinib combined with either ribociclib or NVP-AEW541 yielded 
synergistic effect in both DiFi62 and DiFiG variants. Using proteome profiler kits, we found DiFiG cells 
had an increased phosphorylation of EGFR, insulin receptor, IGF-IR and ERK1/2, but HER-2 and HER-3 
were undetectable. A significant increase in the levels of CDK4/6 was observed in DiFi62, but its level of ex-
pression was lower in the DiFiG variant. Moreover, treatment with CDK inhibitors or trametinib was able 
to entirely block the signalling of CDK4/6 and cyclin-D1 in DiFiG cells, but not in DiFi62 cells, suggesting 
that the mechanisms of acquired resistance to anti-EGFR mAb or TKI in these two variants are indeed dif-
ferent. Taken together, our results support further investigation on the therapeutic potential of combining 
CDK4/6 and IGF-IR inhibitors in CRC cells with acquired resistance to anti-EGFR mAb.
41.   ATP-binding cassette - transporter upregulation; a potential mechanism of resistance to 
        CDK7 inhibitors THZ1 and ICEC0942
Georgina P. Sava, Charles Coombes, Laki Buluwela, Simak Ali
Division of Cancer, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital 
Campus, London, UK
Cyclin-dependent kinase (CDK)7 is necessary for transcription initiation, via phosphorylation of the C-
terminal domain of RNA polymerase II, and for cell cycle progression, through T-loop phosphorylation 
of the cell cycle CDKs. Recently it has been shown that CDK7 inhibition may be a useful novel approach 
in the treatment of multiple cancer types. We have developed a new, orally bioavailable selective CDK7 
inhibitor, ICEC0942, that is currently being evaluated in a Phase I clinical trial for advanced solid malig-
nancies. Drug resistance is currently a major problem facing cancer treatment and cancer cells are able to 
evade therapy via a multitude of mechanisms, therefore we sought to identify mechanisms by which can-
cer cells may become resistant to CDK7 inhibition. Through long-term drug exposure, we have developed 
MCF7 breast cancer cell lines that are resistant to both ICEC0942 and the covalent CDK7 inhibitor, THZ1. 
Importantly, whilst cells exposed to ICEC0942 develop resistance to both ICEC0942 and THZ1, cells cul-
tured long-term with THZ1 retain sensitivity to ICEC0942. We have identified upregulation of multi-drug 
resistance ATP-binding cassette (ABC) transporters in the resistant cell lines. Specifically, the ICEC0942- 
and THZ1-resistant cells have upregulation of ABC subfamily B member 1 (ABCB1) or MDR1 and ABC 
subfamily G member 2 (ABCG2) or BCRP, respectively. Increased ABC-transporter mediated efflux activ-
ity was confirmed using flow cytometry and verapamil and novobiocin, specific inhibitors of ABCB1 and 
ABCG2, were able to rescue CDK7 inhibitor sensitivity in the relevant resistant cell lines, demonstrating 
the importance of ABC-transporter activity in these resistance models. In conclusion, we have identified 
ABCB1 upregulation as a common mechanism of resistance to ICEC0942 and THZ1, and ABCG2 upregu-
lation as a mechanism of resistance to THZ1. Overall, we hope that identifying potential mechanisms of 
CDK7 inhibitor resistance will help guide their future clinical use.
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42.   Myosin II reactivation and cytoskeletal remodelling as a hallmark and a vulnerability in 
        melanoma therapy resistance 
Jose L. Orgaz1, Maria Romina Girotti2,3, Eva Crosas-Molist1, Amine Sadok4, Anna Perdrix-Rosell1,5, 
Irene Rodriguez-Hernandez1, Silvia Mele1, Florencia Veigas2, Mirella Georgouli1, Victoria Bridgeman5, 
Panagiotis Karagiannis1,6, Pahini Pandya1, Lena Boehme1, Matthew Smith3, Gabriela Gremel3, Rebec-
ca Lee3, Elena Galvani3, Franziska Baenke3, Paul C. Lorigan7, Fredrik Wallberg4, Amaya Viros3, Ilaria 
Malanchi5, Sophia Karagiannis1, Richard Marais3, Victoria Sanz-Moreno1 
1King’s College London, London, UK
2Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
3Cancer Research UK Manchester Institute, Manchester, UK
4The Institute of Cancer Research, London, UK
5The Francis Crick Institute, London, UK
6University Hospital of Hamburg Eppendorf, Hamburg, Germany
7The University of Manchester, Christie NHS Foundation Trust, Manchester, UK
Targeted and immunotherapies improve survival of a proportion of melanoma patients. However, lack of 
response or therapy resistance are persistent problems in melanoma management. In this study, we provide 
evidence that early adaptation to treatment and acquisition of resistance to MAPK inhibitors (MAPKi) in-
volve profound cytoskeletal remodelling. This is concomitant with changes at the transcriptomic and phos-
pho-proteomic level of many cytoskeletal proteins. Most significant changes are observed in the ROCK-
Myosin II pathway, widely studied for its key role in cancer invasion and metastasis. Furthermore, we find 
that MAPK signalling itself positively controls Myosin II activity. After initial therapy response, drug-
resistant clones restore MAPK and, in turn, Myosin II levels by increasing expression of myosin light chain 
2, ROCK, LIM kinase and myocardin-related transcription factor. Cross-resistance to MAPKi and immune 
checkpoint inhibitors has been recently proposed to be controlled by common transcriptomic alterations. 
We report that high ROCK-Myosin II activity and its characteristic transcriptome identify both targeted- 
and immunotherapy-resistant melanomas. Importantly, resistant cells are more dependent on Myosin II 
activity for their survival. ROCK1/2 or Myosin II activity blockade with either small molecule inhibitors or 
RNAi depletion induces death of resistant cells through a combination of cell cycle defects and decreased 
survival signals. Furthermore, efficacy of both targeted and immunotherapies can be greatly improved by 
combining such therapies with ROCK inhibitors in vivo. Therefore, we propose that a subset of targeted 
and immunotherapy-resistant melanomas is more vulnerable to ROCK-Myosin II inhibition, which opens 
up clinical opportunities for combination therapies. This work is currently under revision for Cancer Cell.
43.   HIF-mediated suppression of DEPTOR confers resistance to mTOR kinase inhibition in 
        renal cancer
Jogitha Selvarajah, Shruthi Devkumar, Hong Doan, Alexander Parsons, Francesc Miralles, Ve-
ronica A. Carroll
St George’s, University of London, Cranmer Terrace, London SW17 0RE, UK
Kidney cancer is diagnosed in over 300,000 individuals annually. Most kidney tumours are clear cell renal 
cell carcinomas (ccRCC) and metastatic disease is still largely incurable, despite some advances in targeted 
therapeutics. However, both intrinsic and acquired drug resistance are major causes of failure of targeted 
therapy in ccRCC. Mechanistic target of rapamycin (mTOR) is a fundamental regulator of cell growth and 
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metabolism. The mTOR signalling pathway is upregulated in ccRCC and is an important therapeutic tar-
get, but some mTOR inhibitors do not work as expected, particularly second generation ATP-competitive 
mTOR kinase and dual PI3K/Akt/mTOR drugs. We have uncovered a resistance pathway to mTOR kinase 
inhibition which is mediated by DEP-domain containing mTOR-interacting protein (DEPTOR). DEPTOR 
is an endogenous inhibitor of mTOR and is critical for mTOR homeostasis and coordinated negative feed-
back control to PI3K/Akt. Here, we show that DEPTOR is strikingly suppressed in ccRCC tumours and 
cell lines. We demonstrate that DEPTOR is repressed by both hypoxia-inducible factors, HIF-1 and HIF-2, 
which are upregulated in renal cancer. DEPTOR knock-in and CRISPR/Cas9 mediated knock-out experi-
ments show that DEPTOR is growth inhibitory in ccRCC. Furthermore, loss of DEPTOR confers resistance 
to second generation mTOR kinase inhibitors through deregulated mTORC1 feedback to PI3K/Akt. Our 
work reveals new mechanistic insight into deregulation of mTOR in ccRCC that is mediated by HIF-de-
pendent reprograming of mTOR/DEPTOR networks. Importantly, we have identified a hitherto unknown 
mechanism of resistance to mTOR kinase targeted therapy in ccRCC. This work suggests that restoration 
of DEPTOR in ccRCC will confer sensitivity to mTOR kinase inhibition.
44.   Acquired resistance to the experimental cancer drug capivasertib is associated with 
        altered cap-dependent protein translation
Jasmine M. Jakubowski1, Denis T. Akan1,2, Mike I. Walton2, Michelle D. Garrett1
1School of Biosciences, University of Kent, Canterbury, UK
2The Institute of Cancer Research, London, UK
The PI3K/AKT/mTOR (PAM) pathway is important for regulating cell growth, proliferation and survival 
in the cell and its deregulation is commonly observed in many cancers. For this reason, PAM inhibitors are 
undergoing development as a novel form of targeted cancer treatment. Since emergence of drug resistance 
is the major problem facing novel targeted therapies, our aim is to identify resistance mechanisms against 
the novel ATP-competitive AKT inhibitor capivasertib (AZD5363), which has currently completed Phase 
II clinical trials. The A2780 ovarian carcinoma cell line was used as a model to identify resistance mecha-
nisms against capivasertib. A resistant subpopulation (5363R) was generated by dose escalation exposure 
to the drug and subcloned. These were investigated against the parental to identify molecular changes. We 
found that the A2780-5363R cells exhibit cross-resistance to both ATP-competitive (17.5 fold difference 
in GI50) and allosteric AKT inhibition (8.4 fold) and to inhibitors further downstream the PAM pathway. 
These include the rapalogue everolimus (78.7 fold) and the mTOR kinase inhibitor vistusertib (3.9 fold). As 
4EBP1 phosphorylation is understood to be a rapalogue-resistant function of mTORC1 and coupled with a 
reduction of 4EBP1 in the resistant cells, 4EBP1 was identified as a potential candidate resistance mecha-
nism. Pull-down of eIF4E showed reduced 4EBP1 and increased eIF4G binding to eIF4E in the 5363R cells, 
independent of mTOR inhibition thus suggesting an increase in cap-dependent protein translation. Protein 
synthesis analyses are consistent with this finding. These results show that increased protein translation is 
a mechanism of acquired resistance to AZD5363. 
45.   FLIPi: evaluating a novel therapeutic strategy to target advanced prostate cancer
Daniel Turnham1, Norman Maitland2, Andrea Brancale3, Andrew Westwell3, Rhiannon French1, 
Richard Clarkson1
1European Cancer Stem Cell Research Institute, School of Bioscience, Cardiff University, Cardiff, UK
2Department of Biology, University of York, York, UK
3School of Pharmacy, Cardiff University, Cardiff, UK
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Current treatment strategies for non-metastatic localised prostate cancer patients classified as “high risk” 
rely upon either radical prostatectomy or radiotherapy followed by androgen deprivation therapy. De-
spite these interventions, a significant proportion of patients with high-risk disease acquire resistance 
and progress with metastasis which will ultimately result in death. Increasing evidence suggests that a 
small population of tumour-initiating cells, cancer stem cells (CSCs), are responsible for this progression 
and are capable of evading, or are refractory to, standard therapies. Targeting CSCs therefore offers an 
interesting therapeutic strategy which should offer more sustained responses to treatment. We have re-
cently shown that inhibiting the anti-apoptotic protein cFLIP in breast cancer cells dramatically sensitizes 
CSCs to the targeted apoptotic agent TRAIL, resulting in a profound decrease in experimental metastasis. 
cFLIP is overexpressed in localized high-grade prostate tumours, and as these tumours are associated 
with increased-risk of metastasis, we hypothesize that cFLIP may play a similar role in the maintenance 
of CSCs in prostate cancers. Using a novel pharmacological inhibitor of cFLIP (OH14) developed in our 
laboratory we have confirmed that cFLIP suppression combined with TRAIL treatment selectively targets 
prostate CSCs in both established and patient derived cultures. Furthermore, OH14 alone has shown efficacy 
as a monotherapy at reducing bulk cell viability in low grade primary prostate cancers. Interestingly, we have 
found cFLIP to be overexpressed in the metastatic subline PC-3M, with OH14 and TRAIL treatment signifi-
cantly reducing bulk and CSC activity in these cells. We are now utilising orthotopic models of metastatic dis-
ease as well as developing a variety of PDX models to investigate how this combination acts in vivo whilst 
also investigating the role of cFLIP in models of acquired resistance to both docetaxel and enzalutamide in 
vitro. We believe that this CSC-based therapeutic intervention may have the potential to halt the spread of 
disease and prevent recurrence in high-risk patients, which no current treatment option is able to do. 
46.   Chronic Myeloid Leukaemia Resistance to Therapy: running on RUNX1
Naomi Gibson, Geetha Bheeshmachar, Peter Laslo
Faculty of Medicine and Health, University of Leeds, St James’s Hospital, Leeds, UK
Chronic Myeloid Leukaemia (CML) is associated with the BCR-ABL1 (BA) tyrosine kinase oncogene and 
managed with drug therapy [Imatinib (IM)]. However, 20% of patients develop drug resistance, resulting 
in fatality within 18 months. A preclinical model of IM resistance using a CML cell line (KCL-22 cells) 
established that IM resistant (IMr) cells are kinase independent, recapitulating clinical observations where 
treatment inhibits BA activity yet the cells continue to survive. Therefore, the IMr cells must acquire new 
oncogenic drivers that compensate for the loss of BA activity. Gene expression analysis revealed that > 1,400 
genes are differentially regulated in IMr cells. Among these genes, the haematopoietic transcription factor 
RUNX1 was of particular interest, being dysregulated in multiple haematological malignancies. RUNX1 
expression is upregulated upon IM resistance in CML patients and our pre-clinical model, and RUNX1 
protein is highly induced in the IMr cells. Knockdown of RUNX1 using two different siRNA constructs 
caused growth inhibition of IMr cells. Further analysis revealed that RUNX1 depletion induced a macro-
phage-like morphology of IMr cells and the upregulation of myeloid-associated genes including CD11b and 
MCSF-R, suggesting that RUNX1 depletion results in partial differentiation of IMr cells. Pharmacological 
inhibition of RUNX1 activity replicated these results, highlighting its potential as a therapeutic target. 
47.   Downregulation of SLFN11 confers resistance to DNA damaging agents; insights into 
        resensitization with novel DNA damage response inhibitor combinations
Claudia Winkler1, Tarrion Baird2, Michael P. Menden1, Jenni Nikkilä1, Martine P. Roudier2, 
Gemma N. Jones2, Andrew J. Pierce2, Mark O’ Connor1, Elisabetta Leo1
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2Oncology Translational sciences, IMED Biotech Unit, AstraZeneca, Cambridge, UK
Schlafen 11 (SLFN11) is a putative DNA/RNA helicase only found in humans and some primates, with bi-
modal distribution in cancer cells. It was initially discovered by bioinformatics analyses of cancer cell da-
tabases as a genomic determinant of response to various DNA damaging agents (DDA). Most importantly, 
recent reports indicate that SLFN11 expression in tumours may serve as a predictive biomarker for strati-
fication of cancer patients treated with DDA and DNA damage response inhibitor (DDRi). In the Sanger 
panel of cancer cell lines, we independently validated SLFN11 downregulation in ~50% of cells, and that its 
expression correlates with response to DDA as well as PARP inhibitors. To further shed light on SLFN11 
mechanism of action we knocked out SLFN11 (KO) in prostate cancer cells DU145 via CRISPR-Cas9. Rel-
evant clones were selected and the isogenic pair was profiled for SLFN11 downregulation at protein levels 
(by western blotting and immunofluorescence) and were instrumental for the development of an FFPE im-
munohistochemistry (IHC) assay. This was further implemented and validated in xenograft tissue and was 
found to be specific. The susceptibility of SLFN11 KO cells to different DDAs and DDRi was verified by cell 
viability assays. Downregulation of SLFN11 conferred resistance to treatments with the topoisomerase in-
hibitors ETP and camptothecin (CPT), as well as to various DDRi. Interestingly, combinations of ETP with 
some DDRi were found to be more synergistic in SLFN11 KO than in wild type cells, suggesting that these 
combinations could be more effective in cells that lack SLFN11. A detailed analysis of these results will be 
presented here and indicate that selective DDA-DDRi strategies may re-sensitize cancers that have become 
resistant to chemotherapy due to SLFN11 downregulation.
48.   Changing faces of FUS: FUS/TLS represses androgen receptor activity in prostate cancer 
        through disruption of the transcriptional complex
G. N. Brooke1,2, R. C. Culley1, F. M. Fioretti1, C. Reader1, E. Rees2, S. M. Powell1, M. Alkheilewi2, 
A. Pine2, L. Latonen3, T. Visakorpi3, L. Gaughan4, D. A. Leach1, J. Waxman1, C. L. Bevan1
1Imperial College, London, UK
2University of Essex, Colchester, UK
3University of Tampere, Finland
4Newcastle University, UK
Prostate cancer growth is dependent upon the androgen receptor, a ligand-dependent transcription fac-
tor which exerts its effects on transcription in concert with cofactor proteins (coactivators and corepres-
sors). We have previously shown that FUS/TLS, a multi-functional protein, is down-regulated in response 
to androgen receptor signalling and that it has tumour suppressor properties. To better understand what 
FUS regulates to block tumour growth, the transcriptome of the androgen-dependent prostate cancer cell 
line LNCaP was investigated in response to FUS over-expression. This analysis identified a high degree 
of overlap between FUS-regulated genes and those regulated by the androgen receptor.  Further, FUS was 
found to predominantly repress androgen receptor activity and this was confirmed using reporter assays. 
Mammalian 2-hybrid and trans-repression assays demonstrated that FUS interacts with the androgen re-
ceptor via its RNA recognition motif domain and contains both transrepression and activation domains. 
Interestingly, the transrepression domains are HDAC independent and do not contribute to the repressive 
action of FUS upon the androgen receptor. Instead, it appears that FUS represses androgen receptor activ-
ity as a result of competition for coactivators. A modified mammalian 2-hybrid assay demonstrated that 
the N-terminal activation function of FUS interacts with coactivators such as SRC1, and chromatin immu-
noprecipitation studies demonstrated that FUS inhibits the formation of the active androgen receptor tran-
scriptional complex. In agreement with our previous findings, FUS levels were reduced in prostate cancer, 
but interestingly were elevated in the aggressive, castrate resistant stage of the disease. It therefore appears 
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that FUS is down-regulated in prostate cancer, reducing the levels of an androgen receptor repressor.  In 
contrast, FUS levels are increased in advanced therapy resistant prostate cancer, suggesting that it may play 
a different role in this late stage of the disease. 
49.   Targeting phospholipase C as a novel therapeutic option for the treatment of prostate cancer
Mohammad Alkheilewi1, Andrea Mohr1, Ralf Zwacka1, Metodi Metodiev1, Euphemia Leung2, 
Michelle Van Rensburg2, David Barker2, Johannes Reynisson2, Greg Brooke1
1Univeristy of Essex, Colchester, UK
2University of Auckland, New Zealand
Prostate cancer (PCa) growth is driven by the androgen receptor and hence therapies often target this sig-
nalling axis. Although successful initially, the treatments invariably fail and the tumours progress to the 
aggressive castrate resistant stage of the disease. There is therefore a great need for novel therapeutics for 
castrate resistant disease. Thieno[2,3-b] pyridines anticancer compounds were discovered by virtual high 
throughput screening as potential inhibitors of phospholipase C, which has been shown to promote tu-
mour growth and metastasis. These compounds have been previously demonstrated to be effective inhibi-
tors of breast cancer. Here we expanded the research by investigating the efficacy of these compounds on 
PCa cell lines. Using growth assays, flow-cytometry analysis, florescent imaging and cell tracking assays 
I have demonstrated that the compounds are potent inhibitors of PCa proliferation and motility. Impor-
tantly, some of the compounds show less activity in the non-tumorigenic control BPH1, suggesting that 
these drugs are more specific for cancer cells. Interestingly, the drugs were also found to induce multi-nu-
cleation, G2/M arrest and promote apoptosis. In conclusion, these compounds represent a novel therapeutic 
approach for PCa and further work to assess their efficacy is warranted.
50.   Nanodelivery of CYP26 inhibitors enhances the actions of retinoic acid in 
        neuroblastoma-derived tumour cells
Shreya Shah1, Maja Bilip1, Mayuran Mathiyalakan1, Aris Tagalakis1, Stephen Hart1, 
Claire Simons2, Andrew W. Stoker1
1UCL Great Ormond Street Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK
2School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, UK
Neuroblastoma is a paediatric, sympathetic nervous system cancer in which the five-year survival of 
high grade tumour patients remains poor. After multimodal treatments, patients receive residual disease 
therapy with retinoic acid (RA), a natural, vitamin A-derived neural differentiation agent. While RA can 
modestly improve survival, it is beset with challenges of effective dosing, toxicity and evolved resistance. 
RA in particular suffers poor pharmacokinetics due to its rapid metabolism by CYP26 enzymes and these 
enzymes are also thought to be responsible for some forms of RA resistance. RA efficacy might thus be 
improved through CYP26 inhibition in tumour cells. Given the highly hydrophobic nature of many CYP26 
inhibitors, we also hypothesized that inhibitor bioavailability may be further improved through liposomal 
nanodelivery. Several RA metabolism-blocking agents (RAMBAs) exist as inhibitors of CYP26 enzymes, 
but these have not so far been tested for their abilities to either increase neuroblastoma cell differentiation, 
or enhance the suppression of cell growth in response to RA. Here we demonstrate that the bioavailability 
of these hydrophobic RAMBAs can be facilitated using liposomal nanoparticles. In RA-treated neuroblas-
toma cell lines, we show that both ethanol-solubilized and liposome-loaded RAMBAs can successfully 
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enhance the actions of RA, generating increased cell differentiation, suppression of cell proliferation and 
suppression of the neuroblastoma driver protein N-Myc. We propose that the nanodelivery of RAMBAs 
may provide a new approach for effective enhancement of RA action in neuroblastoma, potentially revers-
ing some forms of CYP26-based RA resistance, and facilitating more selective tumour targeting of these 
agents.
51.   Acquisition of a mesenchymal phenotype in endometrial cancer through epigenetic 
        manipulation may contribute to therapeutic resistance
L. D. Ordonez1, L. Blake1, L. Margarit2, D. Gonzalez1, P. Rees3, L. Francis1, R. S. Conlan1
1Reproductive Biology and Gynaecological Oncology Group, Swansea University Medical School 
2Abertawe Bro Morgannwg University Health Board 
3College of Engineering, Swansea University 
Endometrial cancer (EC) is the most common gynecological cancer and the fourth most common cancer 
in females in the UK. Classified into two histotypes, Type I correlates with estrogen receptor-positivity (ER) 
and good prognosis while Type II, presents as ER-negative, high-grade disease with poor prognosis. Despite 
advances in treatment, intrinsic and acquired resistance is a major problem, hindering the effectiveness 
of drugs in the clinic. A better understanding of the mechanisms that determines resistance could make 
a significant impact. To investigate the role of epigenetic instability in driving cellular changes in EC we 
utilized cell lines to model Type I (Ishikawa) and Type II (Hec50) treated in vitro with the de-methylation 
drug 5-Aza-Cdr. Ishikawa were more sensitive to treatment than Hec50. Hec50 cells showed a higher pro-
portion of cells with mesenchymal morphology and sublethal doses of 5-Aza-Cdr for 96 hours resulted in 
an increase in mesenchymal cells in both cell lines. These changes correlated with a decrease in E-cadherin 
in Ishikawa and increase in N-cadherin in Hec50, suggesting partial epithelial-to-mesenchymal transition 
(EMT). EMT has previously been shown to correlate with invasion and treated cells showed promoter de-
methylation of genes that contribute to invasion (MMP9, MMP12, CXCL12) in both cell lines, correlating 
with biophysical alterations suggestive of increased cellular motility. Treated Hec50 were cultured for a fur-
ther four weeks and showed the mesenchymal population was the most prominent to remain, suggesting 
that this population could contribute to resistance. In conclusion our work suggests that a mesenchymal 
phenotype may be involved in intrinsic and acquired resistance to therapy in EC, with a subpopulation of 
cells acquiring a partial transition, as a result of epigenetic manipulation, during early stages of treatment. 
Such mechanisms, well documented in breast cancer, are targets for next generation drugs, which may 
present advantageous therapeutic strategies in the uterus. 
52.   By-pass of irinotecan resistance by the potent topoisomerase I inhibitor LMP400 
Jan Stenvang1, Yves Pommier2, Niels Frank Jensen1, Mark Cushman3, Mark Roger4, 
Nils Brünner1
1University of Copenhagen, Institute of Drug Design and Pharmacology & Scandion Oncology, Copenhagen, 
Denmark 
2Development Therapeutics Branch and laboratory for Molecular Pharmacology, Center for Cancer Research, 
National Cancer Institute, NIH, Bethesda, MD, USA
3Department of Medicinal Chemistry and Molecular Pharmacology, and The Purdue Center for Cancer Re-
search, Purdue University, West Lafayette, Indiana 47907, USA
4Gibson Oncology, Miami, FL 33109, USA
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Irinotecan is a topoisomerase I inhibitor used to treat patients with metastatic colorectal cancer (CRC). 
However, although approximately 50% of these patients will initially benefit from first-line irinotecan-
containing treatment, they will all experience progressive disease. We developed pairs of SN38-sensitive 
and SN38-resistant human CRC cell lines (Jensen et al., Mol. Oncol, 2015). Two of three cell lines had sig-
nificant upregulation of ABCG2 and inhibition of this drug efflux pump with a synthetic inhibitor (Ko143) 
abolished SN38 resistance in ABCG2-upregulated cell lines. An alternative to using pump inhibitors to 
block topoisomerase I inhibitor resistance is to use topoisomerase I inhibitors that are not substrates for 
ABCG2. LMP400, which belongs to the indenoisoquinoline family, was identified from the NCI60 data 
files as a potent topoisomerase I inhibitor. We exposed ABCG2-upregulated SN38-resistant cell lines to 
LMP400 and observed a highly significant anti-tumor effect indicating that LMP400 is not a substrate for 
the ABCG2 efflux pump. Another notable feature of LMP400 is that it - in contrast to SN38 - is not metab-
olized by UGT-1A1 and it is therefore not expected to result in severe side effects in patients with mutated 
UGT-1A1. Finally, LMP400 was also active in colorectal cancer cell lines with acquired oxaliplatin resis-
tance. LMP400 has passed clinical phase I studies in various cancer types with incurable disease (Kummar 
et al., Cancer Chemotherapy Pharmacol, 2016). The recommended dose for phase II studies is weekly 90 
mg/m2 with myelosuppression as the primary toxicity and with only limited GI side effects. We will initiate 
a study in patients with metastatic CRC progressing on irinotecan-containing chemotherapy. We will fol-
low Simons two stage design with ≥ 2 responders among 15 patients (RECIST version 1.1) being sufficient 
to include an additional 10 patients.  
53.   SCO-101 is a first-in-class drug that reverses anti-estrogen resistance in breast cancer cells
Katrine Hartfelt1, Ida Christina Barner Madsen1, Signe Lykke Nielsen1, Palle Christophersen2, 
Nils Brünner1,3, Jan Stenvang1,3
1Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Co-
penhagen, Jagtvej 160, Copenhagen DK-2100, Denmark 
2Saniona, Baltorpvej 154, Ballerup DK-2750, Denmark 
3Scandion Oncology, COBIS, Ole Maaløesvej 3, Copenhagen DK-2200, Denmark 
Eighty percent of all cases of breast cancer patients present with estrogen receptor (ER)-positive disease 
and treatment with anti-estrogens is an effective treatment for these patients. However, anti-estrogen re-
sistance uniformly arises in patients with advanced breast cancer. SCO-101, which is an inhibitor of the 
volume regulated anion channel (VRAC), is an oral drug, which exhibits a safe toxicology profile as dem-
onstrated in four phase I clinical trials in healthy individuals. We investigated the potential of SCO-101 
to act in combination with the anti-estrogens tamoxifen and fulvestrant in anti-estrogen resistant human 
breast cancer cell lines (MCF-7/LCC-2, MCF-7/LCC-9, T47D/TR1) and the ER negative MDA-MB-231. 
Treatment effects were investigated by MTT cell viability assays, siRNA knock-down experiments and 
western blots. SCO-101 only had minor inhibitory effects on cell viability of the cell lines when adminis-
tered alone. However, when combining SCO-101 with tamoxifen or fulvestrant in MCF-7 or T47D anti-
estrogen resistant breast cancer cells, an additive to synergistic effect on cell viability was observed. Thus, 
SCO-101 re-sensitized the anti-estrogen resistant LCC-2, LCC-9 and T47D/TR1 cell lines to tamoxifen and 
fulvestrant. In contrast, SCO-101 in combination with anti-estrogens had no effects on the triple negative 
MDA-MB-231 cell line. As SCO-101 mainly targets VRAC, in which LRRC8A is the essential subunit, we 
investigated whether knockdown of LRRC8A would impact the treatment outcome. No apparent changes 
in response to SCO-101 and anti-estrogens were observed upon knockdown of LRRC8A. Additionally, the 
protein level of LRRC8A was examined upon treatment with anti-estrogens +/- SCO-101 and the treatment 
did not alter LRRC8A protein expression. Our findings suggest that SCO-101 interferes with anti-estrogen 
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resistance in breast cancer. However, more studies are needed before taking SCO-101 into clinical testing 
in patients with anti-estrogen resistant ER positive breast cancer.
54.   SCO-101 - an oral drug that interferes with drug resistance mechanisms in cancer 
Jan Stenvang1, Palle Christophersen2, Nils Brünner1 
1Scandion Oncology A/S, Ole Maaløvs Vej 3, Copenhagen 2200, Denmark; and University of Copenhagen, 
Institute of Drug Design and Pharmacology, Copenhagen, Denmark 
2Saniona A/S, Baltorpvej 154, Ballerup DK-2750, Denmark 
SCO-101 is a volume regulated anion channel modulator initially developed to treat patients with sickle 
cell anemia (SCA). The drug in the form of an oral capsule has successfully passed 4 clinical phase I studies 
in healthy volunteers (n = 92). The studies included different genders, single and multiple dose escalation 
studies and potential influence of simultaneous food intake. The drug was safe with very limited toxic-
ity (slight and reversible increase in serum bilirubin). Pharmacokinetic studies showed a T1/2 of 15 h and 
Cmax on day 1 of 10 μg/mL = 20 μmol/L and at day 14 of 20 μg/mL = 40 μmol/L. Recommended dose for 
phase II was between 100-150 mg/kg. However, due to the increase in serum bilirubin, further develop-
ment for SCA was stopped. SCO-101 significantly increases the effects of certain forms of chemotherapy in 
xenotransplanted human cancers. Moreover, SCO-101 reverts resistance to certain types of chemotherapy 
and antiestrogens. One recently discovered mechanism of action (MoA) of SCO-101 is inhibition of drug 
efflux pumps. Another MoA relates to inhibition of an intracellular signaling pathway being involved in 
drug resistance. Scandion Oncology will initiate clinical phase II studies with breast and colorectal cancer 
patients, consisting of a run-in part with SCO-101 dose escalations together with standard dose of anti-
cancer therapy followed by a regular phase II study, which will follow Simons two stage design. For the 
chemotherapy studies, patients will be treated with one daily oral SCO-101 dose for one week. In week 2, 
patients will receive one dose of chemotherapy while continuing daily SCO-101 oral treatment. In week 
3, there will be a drug holiday. These three weeks will constitute one treatment cycle. After two and four 
cycles, patients will be evaluated for objective response according to RECIST version 1.1. In addition, we 
will record progression-free survival and overall survival. 
55.   The generation of models of acquired resistance using in vitro and in vivo techniques
Steve Wagner, Christopher Hindley, Keisha Hearn, Aurelie Courtin, Tomoko Smyth, Joanne 
Munck, Nicola Wallis
Astex Pharmaceuticals, Cambridge, UK
The development of drug resistance against clinically approved targeted agents remains a major challenge 
for the treatment of various cancers, with patients frequently relapsing after initial response through multi-
ple mechanisms of resistance. In order to identify and target molecules to overcome resistance to clinically 
approved drugs, better models of resistance are required. We have established multiple resistance models 
to targeted agents using a number of different techniques. Resistance was generated both in vitro and in 
vivo in order to mimic the development of acquired resistance in the patient. In vitro resistance was gener-
ated to targeted agents such as vemurafenib and erlotinib by chronic exposure of cancer cell lines driven 
by BRAF (A375, melanoma) and EGFR (HCC827, lung) to these agents over periods of months. Whilst 
the generation of resistance to some agents was relatively straight forward, other models required more 
optimisation and for some agents we struggled to establish a model of resistance in vitro. In vivo resistance 
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was generated by dosing H2228 and HCC827 xenograft bearing mice with the tyrosine kinase inhibitors, 
crizotinib and erlotinib respectively, for prolonged periods of time and subsequently culturing resistant 
tumours ex vivo. The cell lines resulting from both these types of model were the object of detailed analysis 
such as exome sequencing, RNA-Seq and protein analysis to establish mechanisms of resistance. These cell 
lines were subsequently used to test the ability of compounds to overcome resistance both in vitro and in 
vivo. In summary, our data exemplify how different techniques can be employed to study drug resistance 
in vitro as well as in vivo and to identify novel vulnerabilities in cancer cells caused by different resistance 
mechanisms.
56.   Modelling stromal/cancer cell invasion as a platform to assess stromal targeted therapy 
E P. Carter, A S. Wilson, H M. Kocher, R P. Grose
Centre of Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, 
UK 
Cancer cells co-opt their surrounding stroma to facilitate invasion. This is particularly evident in pan-
creatic cancer, which is characterised by a dense stroma largely comprised of activated stellate cells. 3D 
modelling presents an excellent method to analyse cancer/stromal interactions and the effects of potential 
stroma-targeted therapies. However, many of the current models are time-consuming, low-throughput, and 
require extensive processing for analysis. We have developed a fast, semi-high-throughput cancer/stromal 
invasion assay that can be used to dissect cancer/stromal interactions and quantitatively assess therapeutic 
drug action. Pancreatic cancer cells (Miapaca2) are combined with stellate cells (PS1) in spheroids, which 
are subsequently embedded in Matrigel matrix on glass in a 96 well plate format. Over 48 h dramatic cell 
invasion is observed from the central spheroid, with stellate cells leading the collective invasion of cancer 
cells. This is apparent from the confocal imaging of stellate and cancer cell markers, plus the use of fluo-
rescently labelled cells. Measurement of the invasive area serves as a rapid quantitative readout. Fibroblast 
growth factor receptor 1 (FGFR1) activity in stellate cells has been reported to influence cancer cell inva-
sion, and indeed, treatment with the FGFR inhibitor AZD4547 reduces invasion in a concentration-de-
pendent manner. Thus, this model provides a fast, semi-high-throughput system to interrogate molecular 
crosstalk during cancer cell invasion and objectively interrogate both mechanism and efficacy of stromal-
targeted therapies. 
57.   Chemosensitivity associated chromatin conformation changes influence genomic 
        cisplatin-adduct distribution
John Gallon1, Erick Loomis1, Nicholas Martin2, James Flanagan1, Robert Brown1
1Department of Surgery and Cancer, Imperial College London, London, UK
2Trace Element Laboratory, Clinical Biochemistry, Charing Cross Hospital
Changes in chromatin organization are associated with sensitivity/resistance to DNA damaging, anti-
cancer drugs, such as cisplatin; widely used in the treatment of ovarian cancer. However, how chromatin 
conformation changes during the acquisition of resistance and how this influences cisplatin-DNA adduct 
formation are poorly understood. We investigated platinum-adduct distribution in the context of chroma-
tin accessibility in three pairs of cisplatin sensitive and resistant ovarian cancer cell lines, including lines 
isolated from high-grade serous ovarian cancer patients following chemotherapy (PEO1-PEO4). Using 
ATAC-seq we show chromatin accessibility changes distinguishing resistant ovarian cell lines from their 
sensitive counterparts, with regions of differentially accessible (DA) chromatin primarily at intergenic 
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loci. In the A2780-CP70 and PEO1-PEO4 pairs, DA regions were predominantly less accessible in resis-
tant lines while equal doses of cisplatin induced fewer platinum-adducts in the resistant line, as shown by 
inductively-coupled plasma mass spectrometry. Using a novel assay, Pt-ExoSeq, analysis of genome wide 
platinum-adduct distribution distinguished sensitive PEO1 from its resistant counterpart PEO4, when 
treated with doses inducing equal total damage in both lines. Chromatin conformation changes associated 
with resistance influence adduct formation. Thus, we observe reduced adduct formation in PEO4 compared 
to PEO1 at significantly less accessible genomic regions, primarily around gene promoters. However, a set 
of intergenic regions with increased damage in PEO4 show a larger reduction in accessibility. To confirm 
that greater accessibility increases cisplatin-adduct formation, we increased histone acetylation and chro-
matin accessibility using the histone deacetylase inhibitor Vorinostat, before treating with cisplatin. This 
led to greatly increased adduct formation. We show for the first time that platinum-adduct distribution and 
chromatin accessibility analysed genome-wide, can differentiate platinum sensitive and resistant ovarian 
cell lines and suggest a role for chromatin conformation changes in the emergence of drug resistance by al-
tering the distribution of platinum-DNA adducts throughout the genome and hence their cytotoxic effects. 
58.   Increased ERK phosphorylation as a candidate driver of resistance to the experimental 
        cancer drug AT13148
Nathan D. Breeds1, Denis Akan1,2, Mike I. Walton2, Michelle D. Garrett1,2
1University of Kent, School of Biosciences, Canterbury, UK
2The Institute of Cancer Research, CRUK Cancer Therapeutics Unit, London, UK
The AGC family of serine/threonine protein kinases comprises a number of drug targets with therapeutic 
potential for the treatment of cancer. AT13148 is an ATP competitive AGC kinase inhibitor, currently in 
phase 1 clinical trials, with activity against several members of the AGC kinase family, including ROCK 
1/2, AKT, and p70S6K. Due to the prevalence of acquired drug resistance in the clinic, elucidating mecha-
nisms of acquired resistance early in the development of an experimental cancer drug may provide op-
portunities to overcome resistance. The aim of this project was therefore to develop preclinical models of 
AT13148 resistance and identify potential driver mechanisms prior to clinical emergence. Isogenic AT13148 
resistant sub-clones were generated from the A2780 ovarian carcinoma cell line. These displayed increased 
ERK 1/2 phosphorylation concurrent with decreased MEK 1/2 phosphorylation, when compared to the pa-
rental A2780 cell line. In addition, two of the resistant sub-clones were sensitised to AT13148 on exposure 
to the ERK inhibitor GDC-0994, implicating ERK as a driver of resistance. These sub-clones also exhibited 
cross-resistance to MEK inhibitors (PD-0325901 and selumetinib), with ERK phosphorylation shown to be 
refractory to PD-0325901. Loss of DUSP 6 expression, an ERK 1/2 phosphatase, was subsequently detected 
in these AT13148 resistant sub-clones and is hypothesised as a potential mechanism of increased ERK 
phosphorylation and therefore resistance.
59. Identification of candidate genes that may function in oestrogen receptor - breast cancer
Stephen Chandler1, Francesco Crea1, Mark Hirst1, Angela Cox2, Sushilaben Rigas1
1The Open University, Milton Keynes, UK
2University of Sheffield, Sheffield, UK
Breast cancer is the most common cancer in women worldwide. Most breast cancers are hormone related 
involving the oestrogen receptor (ER), progesterone receptor (PR) and/or the human epidermal growth 
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factor (HER2). The majority of aggressive (invasive and metastatic) breast cancers are negative for the ER 
receptor (ER-) including the triple negative and basal subtypes (ER-, PR-, HER2-). Due to this, traditional 
treatments such as hormonal replacement therapy are not suitable. Using bioinformatics, R scripting, and 
datasets from 1,485 Caucasian samples (1,437 tumours and 48 normal tissues) with 21,000 genes from the 
publicly available online GEO database (NCBI), we compared expression levels of ER negative (ER-) tu-
mours to ER positive (ER+) tumours. 7 protein coding genes were identified as candidate functional genes, 
where their expression was significantly up-regulated in ER- tumours (log2 FC= 1.02-1.24, P = 2.98E-31 - 
6.47E-19) which correlated with reduced survival using distant metastasis free survival in Kaplan-Meier 
plotter (Log rank test, P = 0.0013-0.033). Next, we will determine the effect of copy number changes, the 
functions of the genes in triple negative breast cancers and in cellular pathways, and then validate these 
results in the laboratory to test their potential as novel therapeutic targets in aggressive cancers and as bio-
markers to predict prognosis or metastases. 
60.   CRUK-MedImmune Alliance Laboratory: a unique partnership in the discovery and 
        development of novel biologics
Sebastian Fielder, Denice Chan
Cancer Research UK-MedImmune Alliance Laboratory, The Portway Building, Granta Pk, Cambridge CB21 
6GS, UK
In September 2014 Cancer Research UK (CRUK) and MedImmune entered into an innovative collabora-
tion with the aim of setting up a laboratory in Cambridge to develop novel cancer drugs for patients. As 
part of its research review, CRUK identified that it needed to better leverage its biological expertise and 
play a more prominent role in biotherapeutic discovery. At the same time, MedImmune were driving for-
ward towards the potential of more cures and realized the role key collaborations with organizations like 
CRUK could play in the generation of novel oncology therapeutics. Crucial to the success of the Alliance 
is for the lab to receive target proposals from researchers across the UK with and without CRUK funding. 
Our mission: (1) to maximise cancer patient benefit; (2) to run a collaborative research laboratory; (3) to 
actively engage the oncology research community; (4) to partner closely with investigators.
61.   Using tumour deconvolution to identify determinants of anti-tumour immunity and 
        checkpoint blockade response
Ankur Chakravarthy1, Andrew Furness2, Kroopa Joshi2, Ehsan Ghorani2, Kirsty Ford3, Matthew 
J. Ward3, Emma V. King3, Matt Lechner1, Teresa Marafioti4, Sergio A. Quezada2, Gareth J. 
Thomas3, Andrew Feber5, Tim R. Fenton6
1Department of Oncology, UCL Cancer Institute, University College London, London WC1E 6BT, UK; present 
address: Princess Margaret Cancer Centre, Toronto, Ontario M5G 2C4, Canada
2Department of Haematology, UCL Cancer Institute, University College London, London WC1E 6BT, UK
3Cancer Sciences Unit, University of Southampton, Tremona Road, Southampton SO16 6YD, UK
4Department of Pathology, UCL Cancer Institute, University College London, London WC1E 6BT, UK
5Division of Surgery and Interventional Science, University College London, London WC1E 6BT, UK
6School of Biosciences, University of Kent, Canterbury CT2 7NJ, UK
The nature and extent of immune cell infiltration into solid tumours are key determinants of therapeutic 
response. Using a DNA methylation-based approach to tumour cell fraction deconvolution, we report the 
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integrated analysis of tumour composition and genomics across a wide spectrum of solid cancers profiled 
by The Cancer Genome Atlas Project. Initially studying head and neck squamous cell carcinoma, we iden-
tify two distinct tumour subgroups: “immune hot” and “immune cold”, which display differing mutation 
burden, cytokine signalling, cytolytic activity, and oncogenic driver events. We demonstrate the existence 
of such tumour subgroups across 18 further solid cancer types and, using gene expression data from recent 
clinical trials, show that transcriptional signatures of hot tumours are selectively engaged in melanomas 
that respond to immune checkpoint blockade. Finally, we show that treatment-naive hot tumours are 
markedly enriched for known immune-resistance genomic alterations, potentially explaining the heteroge-
neity of immunotherapy response and prognosis seen within this group. Finally, our genomic copy number 
analysis revealed potential targets for “warming-up” cold tumours, including epidermal growth factor re-
ceptor signalling. 
62.   Quantitative live imaging of Ponatinib in vitro enabled by stimulated Raman scattering 
        microscopy
Kristel Sepp1,2, Martin Lee2, Valerie G. Brunton2, Alison N. Hulme1
1EaStCHEM School of Chemistry, The University of Edinburgh, Joseph Black Building, David Brewster Road, 
Edinburgh EH9 3FJ, UK 
2Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, The University of Edin-
burgh, Crewe Road South, Edinburgh EH4 2XR, UK
Ponatinib, a clinically approved tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML), 
has an alkyne moiety in its structure that makes it inherently Raman active in the cellular silent region of 
the Raman spectrum. Stimulated Raman Scattering (SRS) microscopy is a quantitative imaging tool that 
allows spatial and temporal measurements and discrete intracellular registration by combining with fluo-
rescent reporters. In addition, SRS allows quantitative measurements of intracellular drug concentrations. 
This has enabled utilisation of SRS microscopy to image label-free ponatinib with high sensitivity and spec-
ificity in a number of live human CML cell lines. Drug resistance is a widespread problem in CML treat-
ment, where ponatinib resistant patients have very limited treatment options. To better understand pona-
tinib resistance mechanisms, a human CML cell line with acquired ponatinib resistance was developed. 
Ponatinib concentration in parental and ponatinib resistant CML cells was determined and the values 
were found to be comparable to those obtained by quantitative LC-MS. It was found that lysosomal trap-
ping causes a 730-fold increase in drug concentration inside the cell. These studies also provide evidence 
that ponatinib accumulation in lysosomes is a potential CML resistance mechanism, as the intralysosomal 
concentration was increased 1.9-fold in the ponatinib resistant cell line. It was further demonstrated that 
treatment with chloroquine to increase lysosomal pH, reduces the lysosomal concentration of ponatinib by 
2-fold and 2.6-fold in parental and ponatinib resistant cells respectively. This preliminary data suggest that 
chloroquine combination treatment could be useful in ponatinib resistant CML. 
63.   Resistance to chemotherapy used for early and advanced settings in patients diagnosed 
        with triple negative breast cancer - the Kent cancer network experience
Vasileios Angelis, Emily Parsons, Claire Ryan, Catherine Harper-Wynne
Kent Cancer Network, Maidstone and Tunbridge Wells NHS Trust, Hermitage Lane, Maidstone, Kent ME16 
9QQ, UK
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Aim: Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer that is associated with 
poor prognosis. Due to the lack of hormone sensitivity and the significant heterogeneity amongst triple 
negative breast cancer there are no approved targeted therapies and cytotoxic chemotherapy remains as 
the standard treatment. Although response rates to chemotherapy in early disease are high, patients with 
TNBC remain at high risk of relapse and prognosis remains poor in comparison to other types of breast 
cancer.  There is currently lack of data on this subpopulation of patients with regards to the resistance to 
chemotherapy used for early disease (primary resistance) and advanced disease (secondary resistance) 
through patients’ clinical treatment pathway.
Methods: Data were collected retrospectively from 163 patients diagnosed with triple negative cancer in 
Maidstone and Tunbridge Wells Hospitals between 2011-2017. Clinico-pathological characteristics and pa-
tient treatment outcomes were obtained by accessing electronic records.
Results: One hundred and sixty-three patients with TNBC were identified with a median age of 57. Of the 
patients who received treatment for early disease, 50 % of the relapses occurred within 12 months of this 
treatment (i.e., primary resistance). 33 patients had metastatic disease, 13 of whom received 1st line pallia-
tive chemotherapy.  Over 50% (6) of patients experienced disease progression in less than 3 months from 
commencing treatment (often termed secondary resistance). Patients who subsequently received 2nd and 
3rd line chemotherapy experienced disease progression in less than 1.5 month.
Conclusion: Rates of disease recurrence are consistent with the literature and early progression on treat-
ments exemplifies the inherent chemo-resistance with this phenotype. Continued basic scientific investiga-
tion is needed to examine resistance and develop targeted treatments for this poor prognosis disease.
64.   Investigating resistance mechanisms to tamoxifen in oestrogen-receptor positive breast 
        cancer
Joanna L. Bird1, Jindrich Cinatl2, Mark Wass1, Martin Michaelis1
1University of Kent, School of Biosciences. Canterbury, Kent, UK 
2Institute of Medical Virology, Clinics of the Goethe-University, Frankfurt am Main, Germany
Tamoxifen is the most commonly used adjuvant therapy used to treat oestrogen receptor (ER) positive 
breast cancer. However, development of resistance to this drug during treatment regimens presents a se-
rious clinical problem. Over the last 20 years, many advances have been made into understanding the 
mechanisms of oestrogen signalling in cancer, and the biology of oestrogen receptors, which helps us pre-
dict how resistance to this drug arises. However, not everything is understood about the mode of action of 
tamoxifen as it is known to have both agonistic and antagonistic properties dependent on tissue type. In 
recent years, it has been increasingly reported that tamoxifen does not just target ERs, although the vast 
majority of its actions are still considered to be facilitated by these receptors. It is thought to also elicit non-
specific actions in vivo, which ultimately alters the scientific community’s perspective of this familiar drug. 
This study introduces a new panel of tamoxifen resistant ER+ breast cancer cell lines. The cell lines have 
been characterised for ER expression, response to endogenous oestrogen, and sensitivity to a range of anti-
cancer agents. 
65.   The efficacy of doxorubicin-loaded nanoparticles in drug-resistant cancer cell lines
Hannah Onafuye1, Stefan Pieper2, Jindrich Cinatl Jr3, Mark N. Wass1, Martin Michaelis1
1University of Kent, School of Biosciences, Canterbury, Kent, UK
2Institute of Pharmaceutical Technology and Biopharmacy, University of Münster, Münster, Germany
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Drug resistance is the most common cause of failure of anti-cancer drug therapies. Nanoparticles have 
been introduced as drug carrier systems for the targeting of tumours and overcoming drug resistance. 
Here, we investigate the sensitivity of cancer cells to doxorubin-loaded nanoparticles made from different 
materials, using a panel of neuroblastoma cell lines and their doxorubicin and vincristine sub-lines. 
66.   Characterisation of triple negative breast cancer cell lines adapted to paclitaxel 
Eithaar M. Al-Barwani1, Jindrich Cinatl Jr2, Mark N. Wass1, Martin Michaelis1 
1School of Biosciences, University of Kent, Canterbury, UK
2Institute of Medical Virology, Clinics of the Goethe-University, Frankfurt am Main, Germany
Triple negative breast cancer (TNBC) is a specific subtype of breast cancer that is negative for the protein 
expression of the oestrogen receptor, progesterone receptor and Human epidermal growth factor receptor 
2. TNBC constitutes 15%-25% of all breast cancers and has been established as being a very aggressive sub-
type, despite patients having good initial responses to chemotherapy. One of the chemotherapeutic agents 
most commonly used as a first line of treatment in TNBC is the microtubule-binding agent paclitaxel. 
Here we introduce a novel panel of TNBC cell lines adapted to paclitaxel including drug sensitivity profiles 
against a range of cancer agents.
67.   Characterisation of non-small cell lung cancer with epidermal growth factor receptor 
        mutation
Tharsagini Nanthaprakash1, Jindrich Cinatl Jr2, Mark N. Wass1, Martin Michaelis1
1School, of Biosciences, University of Kent, Canterbury, UK
2Institute of Medical Virology, Clinics of the Goethe-University, Frankfurt am Main, Germany
Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer-related deaths and is the most 
common type of lung cancer (87%) in the UK. Approximately 70% of the patients present with locally 
advanced or metastatic disease at the time of the diagnosis left with chemotherapy as the most beneficial 
option. NSCLCs harbouring tumour cells characterised by activating epidermal growth factor receptor 
(EGFR) mutations are typically treated using EGFR tyrosine kinase inhibitors (TKIs). However, resistance 
formation is inevitable and multiple mechanisms of TKIs resistance have been reported in EGFR-mutant 
NSCLC. Here, we introduce a novel panel of models of acquired EGFR-TKI resistance in  NSCLC based on 
the EGFR-mutant NSCLC cell lines HCC4006 and HCC827 and their sub-lines adapted to the first genera-
tion EGFR-TKIs Erlotinib and Gefitinib and the second generation EGFR-TKI Afatinib.
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